



Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?

Michael J. E. Marshall[†], Richard J. Stopforth[†] and Mark S. Cragg^{*}

Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom

OPEN ACCESS

Edited by:

Jose A. Garcia-Sanz,
Consejo Superior de Investigaciones
Científicas (CSIC), Spain

Reviewed by:

Daniel Olive,
Institut national de la santé et de la
recherche médicale, France
Manuel Izquierdo,
Consejo Superior de Investigaciones
Científicas (CSIC), Spain

*Correspondence:

Mark S. Cragg
msc@soton.ac.uk

[†]These authors have contributed
equally to this work.

Specialty section:

This article was submitted to Cancer
Immunity and Immunotherapy,
a section of the journal
Frontiers in Immunology

Received: 29 June 2017

Accepted: 19 September 2017

Published: 04 October 2017

Citation:

Marshall MJE, Stopforth RJ and
Cragg MS (2017) Therapeutic
Antibodies: What Have We Learnt
from Targeting CD20
and Where Are We Going?
Front. Immunol. 8:1245.
doi: 10.3389/fimmu.2017.01245

Therapeutic monoclonal antibodies (mAbs) have become one of the fastest growing classes of drugs in recent years and are approved for the treatment of a wide range of indications, from cancer to autoimmune disease. Perhaps the best studied target is the pan B-cell marker CD20. Indeed, the first mAb to receive approval by the Food and Drug Administration for use in cancer treatment was the CD20-targeting mAb rituximab (Rituxan[®]). Since its approval for relapsed/refractory non-Hodgkin's lymphoma in 1997, rituximab has been licensed for use in the treatment of numerous other B-cell malignancies, as well as autoimmune conditions, including rheumatoid arthritis. Despite having a significant impact on the treatment of these patients, the exact mechanisms of action of rituximab remain incompletely understood. Nevertheless, numerous second- and third-generation anti-CD20 mAbs have since been developed using various strategies to enhance specific effector functions thought to be key for efficacy. A plethora of knowledge has been gained during the development and testing of these mAbs, and this knowledge can now be applied to the design of novel mAbs directed to targets beyond CD20. As we enter the "post-rituximab" era, this review will focus on the lessons learned thus far through investigation of anti-CD20 mAb. Also discussed are current and future developments relating to enhanced effector function, such as the ability to form multimers on the target cell surface. These strategies have potential applications not only in oncology but also in the improved treatment of autoimmune disorders and infectious diseases. Finally, potential approaches to overcoming mechanisms of resistance to anti-CD20 therapy are discussed, chiefly involving the combination of anti-CD20 mAbs with various other agents to resensitize patients to treatment.

Keywords: anti-CD20, monoclonal antibody, Fc gamma receptors, Fc engineering, isotype, resistance, combination therapies

INTRODUCTION

Over the last two decades, monoclonal antibodies (mAbs) have become a key part of treatment regimens for many diseases, including cancer. In 1997, rituximab became the first mAb to receive Food and Drug Administration (FDA) approval in oncology for relapsed/refractory non-Hodgkin's lymphoma (NHL), and has since significantly impacted on a vast number of patients with various B-cell malignancies and, more recently, autoimmune disorders (1, 2). For example, addition of rituximab to conventional [CHOP; cyclophosphamide, hydroxydaunorubicin, vincristine (Oncovin),

prednisolone] chemotherapy in diffuse large B-cell lymphoma (DLBCL) has resulted in significantly increased progression-free and overall survival at 10-year follow-up (3, 4). By contrast, treatment success is more modest in conditions such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), where response rates are lower and many patients relapse and/or become refractory to treatment (5). Both the success and failure of rituximab has driven the development of further mAb reagents; leading to an increase in our knowledge of how mAb work and how resistance arises (Figure 1).

Interestingly, although much of the current focus in immunotherapy is on checkpoint blockers and other immunomodulatory mAb; in fact, the majority of mAbs approved for use in oncology are the so-called direct-targeting mAb, such as rituximab (6), which are designed to target tumor cells directly. Indeed, mAbs targeting CD20 represent over a quarter of such tumor-targeting mAbs with more in clinical development for conditions outside of cancer (Table 1). Moreover, as many immunomodulatory mAb such as anti-CTLA-4, GITR and OX40 may function as direct-targeting mAb, by deleting regulatory T cells (Tregs) (7–9), the lessons we have learnt from CD20 likely have further relevance in these settings.

In this article, we review developments arising from targeting CD20 and then discuss a range of approaches that are now being applied to improve efficacy, including new antibodies and combination strategies.

CD20 AS A MODEL TARGET

The pan B-cell marker CD20 remains one of the best studied antibody targets to date. Originally named B1, CD20 was discovered in 1980 as the first specific B-cell marker (47). It is a non-glycosylated tetraspanin of the membrane spanning 4-A family, with two extracellular loops (48–50) containing the epitopes for anti-CD20 antibodies (51).

Early studies showed that CD20 forms homotetramers in the cell membrane, suggesting that it may function as an ion channel, and that it disassociates from the B-cell receptor (BCR) upon mAb binding (52). CD20 is now thought to modulate calcium release arising from the BCR: CD20-deficient mouse cells exhibit decreased calcium signaling downstream of BCR engagement, and human B-cells (Ramos) are unable to initiate calcium signaling in the absence of the BCR despite CD20 crosslinking (53, 54). In mice and humans, loss of CD20 results in defects in the ability to generate antibody responses to certain antigens (55, 56).

Importantly, as well as being expressed on normal B-cells, CD20 was also found to be expressed on the surface of malignant B-cells (57). Furthermore, CD20 is expressed on pre-B-cells from an early stage in their development but is not present on the precursor hematopoietic stem cells from which they are derived, and expression is lost during differentiation into antibody secreting plasma cells (58–60). This expression




FIGURE 1 | Timeline of approvals and recent discoveries arising from the study of anti-CD20 monoclonal antibodies (mAb), with proposals of how efficacy may be further augmented. Top left: timeline of notable clinical developments of anti-CD20 mAb. Bottom left: recent mechanistic insights gained from the study of anti-CD20 mAb. Top right: future strategies required to increase the efficacy of anti-CD20 mAb. Bottom right: technical developments and knowledge required to further inform therapeutic design.

TABLE 1 | Direct-targeting monoclonal antibodies (mAbs) currently approved for use in oncology settings.

Generic name	Brand name	Target	Format	Comments (anti-CD20)	Indication	Food and Drug Administration (FDA) (EMA) approval date/status	Reference
Rituximab	MabThera; Rituxan	CD20	Chimeric IgG1	Type I	NHL	1998 (1997)	(1–5)
Ibritumomab tiuxetan	Zevalin	CD20	Mouse IgG1	Type II, ⁹⁰ Y radiolabeled	NHL	2002 (2004)	(10, 11)
Ofatumumab	Arzerra	CD20	Human IgG1	Type I, binds small CD20 loop	CLL	2009 (2009)	(12, 13)
Obinutuzumab	Gazvya; Gazyvaro	CD20	Humanized IgG1	Type II, glycomodified	CLL	2013 (2014)	(14–17)
Ocrelizumab ^a	Ocrevus	CD20	Humanized hIgG1	Type I	MS	2017 FDA (under review by EMA)	(18, 19)
Veltuzumab ^a	N/A	CD20	Humanized hIgG1	Type I, rituximab backbone	Various (i.e., NHL; CLL; ITP)	Clinical trials and/or FDA orphan drug status	(20, 21)
Ocaratuzumab ^a	N/A	CD20	Humanized hIgG1	Type I, Fc-modified	FL; CLL	As above	(22, 23)
Ublituximab ^a	N/A	CD20	Chimeric hIgG1	Type I, glycoengineered	Various (i.e., CLL; MS; other)	As above	(24, 25)
Cetuximab	Erbix	EGFR	Chimeric IgG1		Colorectal cancer	2004 (2004)	(26)
Panitumumab	Vectibix	EGFR	Human IgG2		Colorectal cancer	2006 (2007)	(27, 28)
Necitumumab	Portrazza	EGFR	Human IgG1		NSCLC	2015 (2015)	(29)
Trastuzumab	Herceptin	HER2	Humanized IgG1		Breast cancer	1998 (2000)	(30, 31)
Pertuzumab	Perjeta	HER2	Humanized IgG1		Breast cancer	2012 (2013)	(32, 33)
Ado-trastuzumab emtansine	Kadcyla	HER2	Humanized IgG1	Drug conjugate	Breast cancer	2013 (2013)	(34, 35)
Brentuximab vedotin	Adcetris	CD30	Chimeric IgG1	Drug conjugate	NHL; large cell lymphoma	2011 (2012)	(36, 37)
Daratumumab	Darzalex	CD38	Human IgG1		Multiple myeloma	2015 (2016)	(38, 39)
Dinutuximab	Unituxin	GD2	Chimeric IgG1		Neuroblastoma	2015 (2015)	(40, 41)
Alemtuzumab	Lemtrada, MabCampath	CD52	Humanized IgG1		CLL; MS	As Campath—2001 (2001) As Lemtrada—2014 (2013)	(42, 43)
Olaratumab	Lartruvo	PDGFR α	Human IgG1		Soft tissue sarcoma	2016 (2016)	(44, 45)

Table modified from (46).

^aAdditional anti-CD20 mAbs in clinical development and/or for clinical indications outside of cancer are also shown. Withdrawn mAbs are excluded.

NHL, non-Hodgkin's lymphoma; CLL, chronic lymphocytic leukemia; MS, multiple sclerosis; ITP, idiopathic thrombocytopenic purpura; FL, follicular lymphoma; NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; GD2, disialoganglioside 2; PDGFR α , platelet-derived growth factor receptor alpha.

pattern is close to ideal for a target antigen: it minimizes the potential for off-target toxicity and retains humoral protection against previously encountered pathogens (61), while allowing for repopulation of the B-cell compartment after cessation of anti-CD20 treatment.

Another property that affords CD20 ideal target antigen status is its expression level: it is highly expressed, with approximately 100,000 CD20 molecules expressed on the surface of normal B-cells (with similarly high levels on most malignant cells) (62), which facilitates efficient target opsonization and deletion (63). Moreover, given the extracellular structure of the molecule, the available mAb binding epitopes are located close to the plasma membrane, a feature that has been reported to facilitate efficient binding and recruitment of effector mechanisms for deletion (64, 65). Perhaps less important but also worthy of consideration are that CD20 has no known ligand to interfere with mAb binding and does not exhibit extracellular post-translational modifications, reducing the variation in, and potential loss of, binding epitopes (49).

TYPE I AND TYPE II ANTI-CD20 ANTIBODIES

Anti-CD20 mAbs also have the capacity to redistribute CD20 within the plasma membrane into lipid rafts (66). Functionally, this redistribution may be important for the role of CD20 in BCR signaling (67). However, it also has significant implications for anti-CD20 antibodies themselves. The ability (or lack thereof) of mAbs to redistribute CD20 into lipid rafts has served as a useful classification system for anti-CD20 antibodies (68, 69). mAbs such as rituximab and ofatumumab that bind CD20 and cause compartmentalization into lipid rafts are classified as type I antibodies, whereas those that bind CD20 but cause no redistribution, such as obinutuzumab, are known as type II antibodies (51). In addition to a convenient basis for antibody nomenclature, the type I/II distinction describes key differences in antibody characteristics: first, opsonization of CD20⁺ target cells with type I mAb results in binding twice as many antibody molecules per cell as a type II antibody (63). This is thought to

be due to differences in the modes of binding between the two antibody types, as suggested by X-ray crystallography structures and tomography analysis of type I and II mAbs in complex with CD20 (70). Type I antibodies are proposed to bind CD20 tetramers in a manner that does not block binding of subsequent antibodies, whereas type II antibodies are thought to bind across the tetramer, blocking the binding of further mAbs (51).

The redistribution of CD20 and the associated mAb into lipid rafts is also functionally important with regard to the antibody effector functions induced. Due to the enhanced clustering of antibody Fc regions, type I antibodies are able to potentially induce complement-dependent cytotoxicity (CDC), whereas type II antibodies do not induce CDC to a similar extent (51). However, type II antibodies have been reported to induce a greater degree of directly induced, non-apoptotic cell death upon binding to target cells (71). This mechanism has been shown in both B-cell lines as well as primary B-CLL cells (72). The enhanced clustering of type I antibodies renders them more susceptible to internalization, resulting in lysosomal degradation and a reduction in surface CD20 expression (73). Known as antigenic modulation, this is thought to be an important mechanism of resistance to type I anti-CD20 treatment.

Importantly, since the very first studies on CD20 mAb carried out with B1 and 1F5 (74), it has been clear that targeting the same surface marker with different mAb can have profound differences in response. Among many other lessons, this has been an important one that study of CD20 has revealed. In fact, subsequent work by Niederfellner et al. revealed that type I and II mAbs bind an extremely similar epitope on the same loop of CD20 and it is likely that only the orientation of binding differs between these mAbs but that this results in profound differences in activity (75).

MECHANISMS OF DIRECT-TARGETING MAB FUNCTION

As alluded to above, therapeutic mAbs are able to elicit multiple effector functions after binding to their target antigen. The study of anti-CD20 mAbs has contributed to the understanding of almost all of these, including signaling through the target molecule, triggering cell death, initiating the complement cascade, and engagement of Fc gamma receptors (FcγRs) triggering FcγR-dependent responses such as target cell lysis or engulfment (76).

Direct Binding Effects

Monoclonal antibody binding can have multiple direct effects on the target cell. For example, binding to a receptor can block binding of the relevant ligand, such as is the case with cetuximab binding the epidermal growth factor receptor (EGFR), inhibiting soluble EGF binding; thereby reducing proliferation and survival signaling to the tumor (26). With CD20, direct effects are again dependent on the mAb type; type I mAb triggering a limited degree of apoptosis, which is likely reflective of BCR signaling and type II mAb provoking a non-apoptotic lysosomal form of cell death (69). How this is triggered is still

the subject of much debate, but is likely related to reactive oxygen species production (77).

Complement-Dependent Cytotoxicity

All anti-CD20 mAb used in the clinic to date have been of the IgG1 subclass and so are able to activate the complement cascade once bound to target-expressing cells, triggering complement-dependent cytotoxicity (CDC). This process begins with the binding of C1q and follows the sequential activation of several proteases that cleave serum complement proteins in a specific order, generating enzymatic complexes that trigger further protein recruitment and processing (78). The end result of the cascade is threefold: the liberation of soluble molecules that act as anaphylatoxins to recruit immune effector cells; the deposition of cell bound cleavage fragments, largely C3b, acting as opsonins promoting target cell phagocytosis; and, finally, formation of a membrane attack complex (MAC) in the target cell membrane (79).

It has recently been shown how the proximity of binding to the membrane affects the effector functions engaged by an antibody, as had been previously suggested by the enhanced complement activating ability of ofatumumab (65, 80). Ofatumumab (2F2) is a type I anti-CD20 mAb (Table 1) that recognizes an epitope comprising both extracellular loops, binding closer to the cell membrane than rituximab (12). This membrane proximity is linked to the increased CDC seen with this antibody compared to rituximab (13). Ofatumumab has shown activity against rituximab-resistant CLL cells *in vitro*, despite their low CD20 expression, and has been approved for CLL treatment (13, 80).

Although CDC has been studied for many years, it was only recently revealed, using mAbs to CD20 and other targets, that IgG adopts a hexameric conformation in order to interact efficiently with the six head domains of C1q (81). The formation of hexamers on the target cell surface results from non-covalent interactions between adjacent Fc regions, increasing C1q binding avidity and subsequent CDC efficacy (81). This observation prompted a series of new developments in mAb engineering. Specific mutations capable of enhancing hexamerization of IgG and hence CDC were identified, namely E345R, E430G, and S440Y (81). Introducing the E345R mutation into anti-CD20 (IgG1-7D8) significantly increased Daudi cell lysis in comparison to wild-type IgG1 (81). In a further study, de Jong et al. showed the applicability of these findings to mAbs targeting different target antigens (i.e., CD52), target cell lines with differing levels of CD20 and complement regulatory proteins, and also confirmed improved efficacy in comparison to wild-type mAb in a tumor model (82).

Despite the obvious potential of such Fc region engineering for enhanced CDC, introducing multiple hexamer-enhancing mutations is likely to be detrimental, as double (E345R/E430G; RG) (82) and triple (E345R/E430G/S440Y; RGY) (81, 82) mutants formed hexamers in solution (RG—7.7%, RGY—73%) (82). RGY also activated complement in the absence of target cells, as measured by C4d generation (81). Although to a lesser degree than double and triple mutants, some single mutants also resulted in the formation of a small percentage of hexamers in solution (1.2% for

E345R), target-independent complement activation, and accelerated clearance of antibody from the circulation (82). However, an important finding was that amino acid substitutions at positions E345 and E430 (resulting in enhanced hexamer formation on the target cell) was not restricted to R and G, respectively. Moreover, when the preferred mutations (E435K or E430G) were introduced into the type I anti-CD20 mAbs 7D8 and rituximab, an increase in CDC in 5/6 CLL samples in comparison to wild-type mAbs was observed (with one of the CLL samples being refractory to CDC due to having a very low CD20 expression).

Intriguingly, it was also shown that the inefficient CDC induced by type II anti-CD20 mAbs (11B8) (82), or an anti-CD38 mAb containing IgG2 and IgG4 Fc regions (81) could be partially overcome by introduction of hexamer-enhancing mutations. Alternatively, the poor CDC mediated by anti-EGFR (2F8) was overcome by forcing monovalent binding of antibody to the target (81), indicating that the orientation of mAbs on the target cell is important for hexamer formation. However, CDC mediated by the type I anti-CD20 mAb 7D8 was not enhanced when only capable of monovalent binding (81). Although rituximab is able to adopt a monovalent binding to target antigens due to a relatively high off-rate (83), this explanation for enhanced CDC in the case of 7D8 is unlikely as 7D8 has a lower off-rate (83) and also induces more CDC in comparison to rituximab in the presence or absence of hexamer-enhancing mutations (82). Nevertheless, these results suggest that the CDC capability of a mAb may be increased by forcing hexamerization at the level of the target, and that a single hexamer-enhancing mutation is probably sufficient. However, what remains to be seen is whether these mutations also augment Fc γ R-mediated mechanisms and elicit greater efficacy *in vivo*.

Fc γ R-Mediated Mechanisms

Unique to IgG antibodies are the effects mediated through the Fc γ R family. These receptors are expressed on many different cell types and are essential for several IgG functions (84). Conventionally, Fc γ R-expressing effector cell functions have been ascribed to either natural killer (NK) cells or myeloid effectors (85). NK cells are able to mediate a direct lytic attack on opsonized target-expressing cells through Fc γ RIIIA [and, if present, Fc γ RIIC (86)] through a process termed antibody-dependent cell-mediated cytotoxicity (ADCC) (87).

Another Fc γ R-dependent mechanism is mediated by phagocytic cells, such as macrophages, monocytes, and neutrophils. Similar to ADCC, opsonized target cells trigger signaling through Fc γ Rs expressed on the phagocyte, resulting in actin rearrangement and extension of the phagocytic cell membrane (88). The membrane eventually engulfs the opsonized cell in a phagocytic vesicle, or phagosome, which then fuses with lysosomes within the phagocyte, resulting in degradation of the phagocytosed cell by lysosomal enzymes (85). This mechanism has been termed antibody-dependent cell-mediated phagocytosis (ADCP). In fact, myeloid cells can elicit both phagocytosis and killing of targets (89).

IN VIVO MECHANISMS OF ACTION

The above described effector functions of IgG can all be readily demonstrated through *in vitro* assays (14, 65). However,

knowledge of the relative importance of these effector functions to *in vivo* efficacy is essential to design optimal treatments.

One method applied to shed light on *in vivo* antibody function has been the retrospective analysis of the impact of Fc γ R polymorphisms in human clinical trials. In some trials, this analysis has revealed a significant correlation between the Fc γ RIIIA V158 polymorphism that encodes for higher affinity binding to IgG1 and clinical response (90, 91). This finding supported the paradigm that Fc γ R-mediated effector functions and particularly ADCC through NK cells, which predominantly express only Fc γ RIIIA, were the dominant effector mechanisms for anti-CD20 mAb. These findings also reinforced the bias that NK cells are the principle effectors for anti-CD20 mAb which derives from studies of human peripheral blood mononuclear cells (PBMCs) and blood (in which key effectors such as macrophages and/or neutrophils are lacking). However, it is important to note that several myeloid cells, including macrophages, also express Fc γ RIIIA and that, more recent, larger oncology trials have failed to show strong evidence for this receptor polymorphism as being central to antibody efficacy (92, 93).

With regard to other effector functions studied in humans, data from samples collected from patients treated with rituximab convincingly show that components of the complement system are depleted after mAb administration, and that supplementation of blood from these patients with additional complement components restores complement-mediated lysis *ex vivo* (94). Furthermore, early studies with rituximab suggested that the expression of complement defense molecules, including CD55 and CD59, on target cells was a predictor of poor response to anti-CD20 treatment (95). However, these studies have not been confirmed (96) and, moreover, several negative associations of complement engagement and mAb effector function have been provided (97, 98). Moreover, a polymorphism in the gene encoding C1qA (A276G), known to influence C1q levels, has been linked to responses to anti-CD20, with FL patients having an AG or AA genotype (lower C1q expression) experiencing a significantly longer time to progression following an initial response to rituximab (99), and patients with DLBCL harboring the AA genotype displaying significantly longer overall survival following R-CHOP (100). This seemingly suggests a detrimental role for complement.

Perhaps the best current models for elucidating *in vivo* effector function are mouse models, which facilitate the manipulation of various effector components to establish their relative contribution to antibody efficacy. Initial studies using mice that are defective in the Fc γ chain, and therefore do not express any activatory Fc γ R, showed no response to anti-CD20 therapy, indicating that activatory Fc γ Rs are absolutely required for anti-CD20 therapy (101, 102). Similar studies in mice lacking the key complement mediators C1 or C3 have argued against a major *in vivo* role for complement as an effector mechanism of anti-CD20 antibodies (73, 103, 104). Thus, it would appear that Fc γ R-dependent mechanisms predominate in mediating anti-CD20 therapy in mice.

Studies in mice trying to identify the key cell type(s) for mAb-mediated anti-CD20 depletion have indicated that NK cells are not essential for antibody therapy, as anti-CD20 therapy was

effective in mouse strains with defective NK cells or after NK cell depletion (103, 105). Intriguingly, in the study by Uchida et al., mice deficient in perforin, one of the main NK cell effector molecules, were still capable of depleting the majority of circulating/splenic B-cells (103) further supporting the absence of a role for NK cells and ADCC as an effector function in anti-CD20-mediated depletion. However, macrophage depletion using clodronate liposomes resulted in impaired deletion of normal and malignant B-cells during anti-CD20 therapy (73, 103, 104). This finding argues that myeloid cells, and particularly macrophages, are the most important cell type for anti-CD20 therapy, at least in mice. Other evidence for this comes from intravital imaging, in which macrophages within the liver (Kupffer cells) were imaged engulfing opsonized B-cells after anti-CD20 therapy (106). As above, clodronate liposomes completely abrogated anti-CD20 mediated B-cell depletion.

Finally, although the evidence for a role of FcγRs and macrophages in the setting of anti-CD20 is unequivocal, a recent study by Lee et al. (107) indicates that next-generation mAb formats may be able to elicit alternative means of activity. Those authors used a library screening approach to select variants of rituximab with enhanced C1q binding but no FcγR binding, and provided evidence that these mAbs can elicit complement-dependent cellular cytotoxicity (CDCC) and complement-dependent cellular phagocytosis (CDCP) in the presence of serum. In comparison to wild-type rituximab, the aglycosylated variant (RA801) with two complement-enhancing mutations (K320E and Q386R) displayed some activity in FcγR-null mice (107) and is, therefore, worthy of consideration as a novel therapeutic; although it should be noted that the models chosen for study represent cell line tumors which may display little complement defense. As such, further experiments are required in fully syngeneic models targeting normal or malignant B-cells in a more physiological setting to confirm these findings, but nonetheless it represents an interesting approach in settings where FcγR-mediated effector functions may be limited.

NEUTROPHILS AS ALTERNATIVE EFFECTORS

As described above, macrophages are now widely recognized as key mediators of ADCC/ADCP of IgG-opsonized tumor cells *in vivo*, particularly with regard to anti-CD20 mAb. However, there have also been recent reports that neutrophils may also be involved or at least capable of effector activity with these reagents. Neutrophils are characterized by expression of the glycosylphosphatidyl inositol (GPI)-linked FcγR, FcγRIIIB (CD16B), and to a lesser extent FcγRIIA (108) and, therefore, may be expected to be activated by IgG-opsonized tumor cells. Given their abundance in the circulation, it is reasonable to suggest that they can elicit robust effector function.

It has long been known that IgG mAbs are capable of inducing neutrophil-mediated cytotoxicity against B-cell targets. For example, although dependent on the target cell line, anti-human leukocyte antigen (HLA) class II IgG mAbs were shown to mediate ADCC by neutrophil effectors with a clear hierarchy

of isotype (IgG1 > 2 > 3 > 4) albeit less than IgA mAbs (109) (see below). Moreover, in the setting of anti-CD20 mAbs, Golay et al. more recently showed that anti-CD20 IgG mAbs are capable of activating neutrophils and inducing tumor cell phagocytosis, at least *in vitro* (15). Consistent with the neutrophil FcγR expression profile, phagocytosis mediated by a glycoengineered variant of rituximab was blocked with F(ab) fragments of either anti-FcγRIII or FcγRII, and to a greater extent with a combination of both. Intriguingly, as for FcγRIIIA, the highly homologous FcγRIIIB was shown to bind with a higher affinity to afucosylated mAbs in comparison to non-glycomodified mAbs (15). In line with this, neutrophil activation (CD11b upregulation, CD62L downregulation, and cytokine secretion) was greater with the glycoengineered (afucosylated) type II anti-CD20 obinutuzumab in comparison to wild-type rituximab. However, comparisons with a non-glycomodified obinutuzumab were not performed in this setting and so the enhanced activation could not be ascribed solely to tighter binding to FcγRIIIB due to afucosylation. Neutrophils were also clearly capable of mediating cytotoxicity of rituximab-opsonized Raji and Ramos cells in a recent study, with an EC₅₀ only slightly higher than with PBMC effectors (107). This was shown to be FcγR dependent, as complement-enhanced, Fc-deficient variants of rituximab (RA801 and RA802) were inefficient in neutrophil-mediated lysis (107). However, these rituximab mutants had restored activity in the presence of neutrophils and serum lacking C9 (so as not to activate MAC formation and classical CDC), with lower EC₅₀'s in comparison to wild-type rituximab, which was blocked by mAbs to the complement receptors (CR) 3 and 4 (107). This shows that in addition to ADCC *via* FcγRs, neutrophils can also participate in CDCC of anti-CD20-opsonized targets *via* CRs.

An alternative effector mechanism of neutrophils was recently proposed by Nakagawa et al., whereby target cell apoptosis is triggered through neutrophil-mediated crosslinking of surface bound rituximab (110). Blocking studies and use of afucosylated rituximab variants suggested that FcγRIIIB was responsible for such crosslinking. Intriguingly, this phenomenon mirrors the FcγR-mediated crosslinking reported for pro-apoptotic anti-TNF-related apoptosis-inducing ligand (TRAIL) mAbs (111). Although neutrophil-mediated ADCC mediated by IgG mAbs, such as in the context of anti-EGFR IgG1 and IgG2 (112), anti-HLA class II (109), or indeed anti-CD20 (107) has been reported, neutrophil-mediated ADCC was not observed in this study (110). This possibly reflects a difference between methods of neutrophil isolation or target cells used. Similarly, no neutrophil activation was observed (as measured by upregulation of CD63 and FcγRI), which is possibly related to the fact that FcγRIIIB is GPI-anchored (without an intrinsic cytoplasmic domain) and, thus, is not expected to signal when crosslinked alone (unless through the crosslinking of associated lipid raft-resident kinases). Nevertheless, this mirrors previous findings whereby the crosslinking of pro-apoptotic anti-Fas (113) or agonistic anti-CD40 mAbs (114, 115) did not require intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing signaling domains of FcγRIIIB. Similarly, although effector functions such as ADCC are clearly dependent on the immunoreceptor tyrosine-based activation motif (ITAM) signaling domains of activatory FcγR (116), FcγR-mediated antigen internalization and presentation to

T cells is seemingly ITAM-independent (117). This indicates that both activatory and inhibitory Fc γ R may function independently of their respective ITAM or ITIM domains.

In addition to this *in vitro* work, *in vivo* evidence for a role of neutrophils in the killing of IgG mAb-opsonized tumor cells has also been provided. Although not in the setting of anti-CD20, neutrophils protected against tumor growth following IgG mAb therapy in subcutaneous solid tumor models (melanoma and breast cancer), in an Fc γ R-dependent fashion (118). However, the model used (solid tumor versus hematological) is important to consider, and utilizing the same conditional neutrophil-depletion strategy in B-cell models involving anti-CD20 treatment would be worthwhile. Indeed, in our own studies, depletion studies showed that anti-CD20 mAb-mediated B-cell depletion was independent of neutrophils (119).

Despite the above findings, neutrophil-mediated phagocytosis following mAb engagement is contentious, as a recent study indicated that neutrophils instead mediate the removal of mAb/CD20 complexes from the target cell, in the absence of phagocytosis or target cell death, in a mechanism known as trogocytosis (120). This activity would be expected to be of detriment to the success of mAb therapy. Surprisingly, this trogocytosis was greater for rituximab in comparison to obinutuzumab. In addition to our work on CD20 modulation (73, 121), this may provide a further/alternative explanation for the improved efficacy of obinutuzumab over rituximab observed in CLL patients (16). Similarly, neutrophils have abundant pro-tumor properties (122), suggesting that recruiting neutrophils by direct-targeting mAbs may be undesirable for clinical outcomes.

In summary, IgG mAbs are clearly capable of activating neutrophils. However, potential detrimental functions (i.e., trogocytosis; pro-tumoural functions) should be considered, and the precise role of neutrophils downstream of IgG mAb therapy requires clarification in further studies. Finally, as discussed below, IgG may not be the optimal isotype for recruitment of the favorable attributes of neutrophils, such as ADCC and cytokine/chemokine release (123).

VACCINAL RESPONSES TO MAB THERAPY

The principle success of anti-CD20 mAb has been the direct deletion of the target cells by the effector mechanisms detailed above. However, deletion of tumor cells and their engulfment by myeloid effectors raises the possibility of the induction of a T-cell-mediated immune response to the foreign (mutated) components of the tumor. Although this concept has existed for several years, strong evidence in humans has not been forthcoming with the possible exception of data showing the *ex vivo* re-stimulation of T cells from a small number of patients post-rituximab therapy (124). Regardless, ascribing this activity to mAb-mediated killing of the tumor following Fc γ R-mediated uptake has not been possible. For this reason, more mechanistic proof of concept has been attempted in mouse models.

Dendritic cells (DCs), *via* their surface Fc γ Rs, are adept at internalizing, processing, and presenting or cross-presenting

antigen (Ag) to CD4⁺ and CD8⁺ T cells *in vivo*, as highlighted in recent experiments whereby Ag was targeted to specific Fc γ Rs (117). In relation to tumors, however, early work showed that DCs, when loaded with immune complex (IC) and transferred into mice, are capable of presenting Ag to T cells and inducing immune responses that lead to tumor elimination in an antigen-specific manner (125). It was also indicated that Fc γ RIIB regulates DC maturation in response to IC and, therefore, the magnitude of anti-tumor T cell responses *in vivo* (126). This was expected based on previous studies showing that Fc γ RIIB regulates the activity of ICs in *in vivo* alveolitis models (127).

An advance came from studies indicating that such T cell responses will develop *in vivo* following anti-CD20 mAb therapy, rather than *via* artificially generated ICs. First, in a series of tumor challenge and rechallenge experiments, Abes et al. showed that when treated with an anti-CD20 mAb, mice were resistant to tumor growth on rechallenge, and this was dependent on the mAb Fc region (128). Recently, the Fc γ R and cellular requirements for such adaptive, vaccinal effects of mAb therapy using the same model were identified. Using a series of experiments involving conditional DC knockouts, Fc-modified mAbs, and humanized mice, DiLillo and Ravetch provided indirect evidence that macrophage ADCC (*via* Fc γ RIIIA), DC uptake of ICs (*via* Fc γ RIIA), and Ag presentation were responsible for the induction of anti-tumor adaptive responses (129).

Intriguingly, both these studies indicated the generation of an adaptive response specific for the CD20 antigen itself, as evidenced by poor survival of mice rechallenged with tumors lacking CD20 (128, 129). Although there are various limitations with these models, such as the utilization of a xenoantigen (human CD20) in mouse (EL4) cell lines, a more recent study also showed that T cells were required for tumor regression of murine A20 tumors following anti-CD20 therapy, as no tumor regression was observed in nude (T cell deficient) mice (130). Notably, Ren et al. also showed a similar requirement for both macrophages [*via* production of type I interferon (IFN)] and DCs in the induction of anti-tumor T cell responses following anti-CD20 therapy, and that CTLA-4^{hi} Treg cells, within larger (more established) tumors, may be responsible for “adaptive resistance.” This lends support for an anti-CD20/anti-CTLA-4 combination regimen. However, the particular tumor model employed is likely important, as the anti-CD20/CTLA-4 combination is not effective in all models (unpublished data).

Despite being slightly different in their T cell subset requirement, with CD4⁺ (128) versus CD8⁺ T cells (130) being more important for primary tumor clearance following anti-CD20 mAb therapy, the mechanisms involved in the various models are not necessarily mutually exclusive. Specifically, IC formation following initial ADCC, which are then internalized/endocytosed and presented/cross-presented by DCs, likely remains the common link. Similarly, the indicated requirement for macrophage type I IFN may help to explain the efficacy of stimulator of interferon genes (STING) agonist/anti-CD20 combination in our own experiments (119). Furthermore, considering the regulatory role of Fc γ RIIB at the level of the DC, it can be hypothesized that anti-Fc γ RIIB mAbs in combination with anti-CD20 mAbs (131) (clinical trial NCT02933320, see below)

may favor enhanced activation of DCs by ICs following ADCC, migration to lymph nodes and stimulation of anti-tumor T cells.

Finally, this phenomenon is likely not limited to anti-CD20 mAbs, as similar observations were made using an anti-human EGFR2 (HER2) mouse model (132). In summary, in addition to the principle 4 mechanisms (direct effects, CDC, ADCC, and ADCP), the vaccinal effect of mAb therapy is emerging as an additional potential mechanism of action for direct-targeting mAbs. The above studies did not measure IC production *per se*. It is, therefore, of interest to determine how changes in the nature of ICs (size/valency) influence the vaccinal response (i.e., between different patients, cancer types and treatments, etc.). Recent studies have attempted to define the relationship between various IC parameters and Fc γ R binding and activation (133), and novel assays for the detection of ICs in serum may also assist this endeavor.

ENHANCING ANTI-CD20 MAB FUNCTION THROUGH Fc ENGINEERING

With the progress outlined above in identifying *in vivo* mechanisms of anti-CD20 antibody therapy and the importance of activatory Fc γ Rs, second- and third-generation anti-CD20 antibodies have been developed which utilize several strategies to try and achieve greater efficacy (Figure 1; Table 1).

Glycoengineering

Removal of the Fc glycans results in a dramatic decrease in binding to Fc γ Rs and complement activation without affecting antigen binding (134–136). This is thought to be due to changes in the constant heavy (CH) 2 domain structure, possibly through the two CH2 domains collapsing to block the Fc γ R/C1q binding site (137). However, the importance of Fc glycosylation extends beyond simply holding the Fc structure in place (138). Shields et al. found that removal of the core fucose residue, present on most recombinant and serum IgG molecules, resulted in increased Fc γ RIIIA binding up to 50 times, translating into increased NK-mediated ADCC (138). Shinkawa et al. confirmed this and reported increased ADCC using low fucose anti-CD20 mAb (139).

In 2006, the structural basis for this increased binding was reported, with Ferrara et al., showing *via* X-ray crystallography that the fucose residue was sterically blocking a stacking interaction between the Fc glycans and those present on the Asn162-linked glycan of Fc γ RIIIA (140). Absence of the fucose resulted in a closer interaction, explaining the increased affinity. As a result of these findings, several afucosylated antibodies have been developed which exhibit the expected increase in Fc γ RIIIA affinity and ADCC. Currently, afucosylated mAbs targeting CD20 (obinutuzumab) or CC chemokine receptor 4 (CCR4) (mogamulizumab) produced *via* cell line engineering have been brought to the clinic and more may follow (141). While other glycoforms have been linked to specific functions, none have been carried forward to the clinic.

Additional glycomodified anti-CD20 mAbs have been developed, further to obinutuzumab. EMAB-6, an afucosylated

anti-CD20 mAb was generated with a view that it may allow lower doses of chemotherapy used in the treatment of CLL (142). This mAb was able to both bind Fc γ RIIIA more tightly and mediate greater NK-mediated ADCC of CLL cells at lower mAb concentrations in comparison to rituximab (142). A later version of this mAb (LFB-R603, now known as ublituximab) was able to elicit maximal ADCC of target Raji cells at a concentration of 1 ng/ml, in comparison to 100 ng/ml for rituximab (143). Moreover, ublituximab recently showed promising efficacy when combined with the Bruton's tyrosine kinase (Btk) inhibitor ibrutinib in a phase II study of relapsed/refractory CLL patients, with ~90% of patients responding, and two complete responses (24). This combination is currently being assessed in a phase III trial of CLL patients (NCT02301156). Another phase III trial for this indication (NCT02612311) has been initiated involving a distinct combination regimen (see below) and ublituximab was placed on Reichart's "Antibodies to watch in 2017" list (18).

On a final note, although the enhancement of ADCC with afucosylated mAbs cannot be disputed, a recent study utilizing mAbs to Rhesus D antigen (RhD) on erythrocytes indicated that afucosylated mAbs do not elicit greater ADCP, in comparison to a clear enhancement in ADCC (144). This led authors to conclude that the benefit of fucose removal may be restricted to cases where NK cells are known to be involved. How this relates to anti-CD20 mAbs is, therefore, of key interest, especially considering the predominant role of macrophages in this setting (see above).

Fc Engineering

While glycosylation is a post-translational modification and, thus, difficult to precisely control, the IgG Fc backbone is readily amenable for mutation to create more efficacious molecules. Mutagenesis libraries have enabled the identification of IgG Fc variants that are aglycosylated but retain Fc γ R binding and effector functions similar to, or even exceeding that of, glycosylated IgG (145, 146). Extensive Fc backbone mutagenesis and an improved understanding of Fc–Fc γ R interactions has enabled the generation of mAbs with increased affinities for Fc γ Rs and effector function (147). Multiple IgG mutations that increase binding for specific Fc γ R, both activatory or inhibitory, have been reported (148). 200-fold increased binding to Fc γ RIIB (but not Fc γ RIIA) was achieved through a Pro:Asp conversion at position 238 and generated IgG with increased agonistic capacity when applied to anti-CD137 mAb (149). Increased binding to Fc γ RIIIA alone, without impacting binding to Fc γ RI or the neonatal Fc receptor (FcRn) has also been reported using an anti-CD20 antibody (150). Increasing binding to activatory Fc γ Rs but not Fc γ RIIB serves to increase the activatory:inhibitory (A:I) ratio (151), enabling greater effector cell activation. A 100-fold increase in ADCC was achieved using Fc mutation to increase Fc γ RIIIA binding (both high- and low-affinity alleles) and applied to several antibodies including rituximab (152). Fc mutations that improve binding to Fc γ RIIA selectively over Fc γ RIIB have also been reported, such as the G236A mutant, which resulted in improved macrophage phagocytosis (153). Furthermore, combination of this mutation with others can result in additive increases in ADCC and ADCP over the wild-type antibody (153).

AME-133v (now known as ocaratuzumab) is an example of an Fc-modified anti-CD20 mAb that is in clinical development for the treatment of B-cell malignancies (Table 1). AME-133v contains two mutations in its Fc region and elicits more efficient ADCC than rituximab with PBMCs from both FcγRIIIA VV158 and VF/FF158 patients (22). Moreover, 5/23 previously treated FL patients responded in a phase I/II clinical trial (22), suggesting potential efficacy. In separate *in vitro* studies, it was also indicated that ocaratuzumab is capable of mediating ADCC of CLL target cells at a greater level than rituximab and ofatumumab, and at a similar level to obinutuzumab (23).

As discussed above, several mutations are also able to promote hexamerization of IgG and elicit potent C1q binding leading to powerful CDC. Although (to the best of the authors' knowledge) the effect of these mutations on FcγR binding has not been reported, there have been some reports that hexamer-enhanced mAb variants also have enhanced FcγR effector functions. To this end, de Jong et al. showed that variants (E345K and E430G) of the type II anti-CD20 mAb 11B8 mediated greater ADCC of Raji cells (82), and improvements in ADCC and ADCP were indicated in the setting of a modified immunomodulatory anti-OX40 mAb (154).

Notably, two situations whereby complement-optimized rather than Fc-optimized mAbs may be beneficial were highlighted in the aforementioned study by Lee et al. (107); reducing potential FcγR-mediated toxicity and FcγRIIB-mediated anti-CD20 mAb modulation, which has been suggested by us to be a rituximab resistance mechanism (73, 121). Finally, the authors speculated that complement-optimized mAb that work independently of FcγRs may be beneficial in the setting of unfavorable FcγR polymorphisms (107).

In addition to optimizing affinity of IgG for C1q and FcγR interaction, mutation strategies optimizing FcRn binding to improve serum IgG half-life has also been attempted to augment efficacy and reduce dosing frequency. Due to the pH-dependent binding of IgG to FcRn, improving the serum half-life of an IgG requires increased binding to FcRn at pH6 (allowing for greater FcRn binding in acidic endosomes) but unaltered FcRn binding at pH7.4 (thereby allowing release at the cell surface) (155). Numerous mutations have been reported to alter FcRn binding at pH6 (156). As an example, the M428L N434S double mutant on the IgG1 background of bevacizumab and cetuximab yielded increased FcRn binding (~10× fold for bevacizumab) and increased half-life in both human FcRn transgenic mice and cynomolgus monkeys (157). As far as we are aware, this technology has not been tested on anti-CD20 mAb. Given the shorter half-life of rituximab due to internalization, such an approach may be beneficial (73). A mAb targeting respiratory syncytial virus carrying the YTE triple mutant (M252Y/S254T/T256E) to increase FcRn binding at pH6.0 has been tested in humans and been reported to increase mAb half-life up to 100 days (158). Further optimization of Fc structure for optimal IgG half-life could enable the tailoring of IgG molecules to suit specific functions, including both therapeutic and also short-term uses such as labeling for imaging (159). Interestingly, enhanced FcRn binding through various Fc mutations has been combined with glycoengineering to generate low fucose

anti-CD20 mAbs with increased serum half-life, FcγRIIIA binding, and ADCC (160).

ISOTYPE SELECTION AND ENGINEERING

All direct-targeting mAbs approved for use in oncology, including anti-CD20 mAbs, are of the IgG class (Table 1). However, it has been questioned whether IgG is the optimal therapeutic Ig class and whether efficacy could be improved by adopting other Ig classes. As expected, many of these proposals have used CD20 as their target of choice.

IgA As an Alternative Ig Class

IgA is important in mucosal immunity (123) and, in contrast to IgG, it has only two isotypes (IgA1 and IgA2) (161). Much of the recent interest in using IgA as a therapeutic isotype has been in its potential to recruit the anti-tumor properties of neutrophils, which express the predominant (although not the only) receptor for IgA (FcaRI, CD89) (123). Crosslinking studies showed that CD89 signaling in neutrophils is efficient, and the use of bispecific mAb constructs (i.e., anti-CD20 × CD89) highlighted that stimulating the interaction between target antigen expressing tumor cells and CD89 on neutrophils efficiently induces cytotoxicity (162). A recent study also indicated that IgA mAbs targeting the melanoma antigen gp75, but not IgG1 or 3, mediated neutrophil ADCC *in vitro* (163). CD89 is also expressed by other myeloid cells including monocytes (and macrophages) (123). Therefore, considering the intricate involvement of macrophages in IgG mAb-mediated target cell depletion (see above), therapeutic IgA mAbs may be able to similarly engage and activate these cells when in sufficient number. However, when compared with IgG, IgA mAbs were limited in their ability to induce mononuclear cell ADCC, which is presumably due to the low percentage (10%) of monocyte effector cells within this cell population, and/or the presence of NK cells (20%) (109) that are not expected to engage IgA mAbs.

Anti-CD20 mAbs of the IgA class have been compared with IgG mAbs in various models. Surprisingly, anti-CD20 IgA2 was capable of mediating CD20 target cell depletion similar to IgG1 in an adoptive transfer model utilizing mice lacking CD89 (164). Pascal et al. also reported activity of IgA2 anti-CD20 in similar adoptive transfer models, although in this setting IgA2 was less effective than IgG1 anti-CD20 (165). Moreover, a different strategy was also employed, whereby DNA constructs encoding anti-CD20 IgG1 and IgA2 were vaccinated following tumor challenge to allow *in vivo* mAb synthesis and, thus, avoid difficulties in IgA purification (165). The survival of mice vaccinated with IgA2 and IgG1 constructs was similar, which is intriguing considering the absence of CD89 expression [as in Lohse et al. (164)]. However, a significantly increased activity of anti-CD20 IgA2 was reported in CD89 transgenic mice in comparison to wild-type mice (165), highlighting the potential for tumor cytotoxicity downstream of IgA interaction with cognate receptor-expressing effector cells *in vivo*.

In these anti-CD20 studies, it was shown that, as expected, IgA mAbs induced neutrophil-mediated cytotoxicity of both cell line and CLL targets to a greater extent than IgG, although

(as expected) the converse was true for mononuclear cells (164). The same trend was observed with anti-HLA class II mAbs (109). Notably, however, IgA was able to recruit more immune cells than IgG in an *in vitro* imaging assay, in a CD89-dependent manner (165). Interestingly, these studies also showed that hIgA anti-CD20 mAbs were capable of inducing CDC of varying CD20⁺ target cells *in vitro* (164, 165). Although of interest, the relevance of this finding *in vivo* is unclear due to retained activity of anti-CD20 hIgA in C1q and C3 knockout mice (164). Despite differences in the kinetics of CDC mediated by IgG1 and IgA2 anti-CD20 being identified, as well as sensitivity to factors such as mAb (165) or serum concentration (164), the unexpected ability of IgA mAbs to induce CDC is nevertheless intriguing from a biological perspective, as IgA antibodies are not expected to engage C1q. Pascal et al. proposed an indirect mechanism for C1q binding downstream of anti-CD20 IgA (165) and recent studies have provided further evidence for a mechanism, now referred to as “accessory CDC,” which occurs in an Fc-independent, BCR-dependent fashion (166). Strikingly, mAbs with no expected CDC functions, namely anti-CD20 F(ab')₂ fragments or IgG4 mAbs with a complement-silencing mutation (K322A), were capable of inducing CDC of BCR⁺ cell lines. The emerging mechanism of such Fc-independent CDC is, therefore, reliant on clustering of the BCR by anti-CD20 mAbs, which favors indirect binding of C1q to surface IgM and subsequent CDC (166). The phenomenon may be limited to anti-CD20 mAbs, as no CDC was observed with IgA1 or IgA2 anti-HLA class II mAbs (109).

IgGA Chimeras

Although IgA mAbs are clearly functional *in vivo*, it is not yet clear how IgA would replace IgG in clinical practice (164). Moreover, IgA molecules have disadvantageous attributes, such as a difficulty of purification and a shorter half-life in comparison to IgG (165). As described, IgA molecules are also not expected to stimulate NK cells, as evidenced by the absence of cytotoxicity observed with mononuclear cells in comparison to IgG (109, 164). For these reasons, there have been efforts to engineer novel mAbs containing the Fc regions of both IgG and IgA, with a view that the resulting molecule will harness the beneficial properties of both Ig classes. Kelton et al. grafted relevant regions of IgA into the Fc region of an anti-HER2 mAb to form a so-called “cross-isotype” IgGA mAb (167). The resulting IgGA mAbs were capable of binding to both Fc α RI and Fc γ R, and induced neutrophil ADCC and macrophage ADCP of HER2⁺ targets similar to IgA molecules, and to a greater extent than parental IgG mAb. Next, as anti-HER2 mAbs did not elicit CDC, presumably due to the biology of the target, and similar to unmodified anti-EGFR (81, 82), anti-CD20 IgGA was generated. This was capable of inducing greater CDC of CD20⁺ targets in comparison to IgA, and greater CDC at lower concentrations than an IgG variant of the same mAb. However, anti-CD20 IgA did induce some CDC, although in contrast to Lohse et al. (164) this was to a lesser extent than anti-CD20 IgG. This is likely related to the “accessory CDC” mechanism (166) mentioned above.

Notably, the IgGA construct did not bind to Fc γ RIIIA or FcRn (167). As this would be predicted to negatively impact

ADCC/ADCP and IgG recycling, respectively, the functionality of IgGA molecules *in vivo* would be interesting to assess. To this end, a recent study assessed the efficacy of a similar anti-CD20 IgGA molecule which had equivalent pharmacokinetics to anti-CD20 IgG1 (168). Anti-CD20 IgGA treatment of tumor bearing mice (transgenic for CD89 on CD14⁺ myeloid cells) led to an improved regression of tumors in comparison to IgG or IgA, in a CD89-dependent manner. Similarly, a peritoneal model was used to show that the activity of IgA or IgGA *in vivo* requires interaction with CD89 on monocytes/macrophages. However, a limitation of this model is that CD89 was restricted to CD14⁺ cells, with no neutrophil CD89 expression. It is also unclear whether the expression level of the CD89 is comparable to that seen in humans.

Alternatively, in contrast to the grafting used to produce the “cross-isotype” IgGA, Borrok et al. fused the entire CH2/hinge of IgA2 onto the C terminus of an anti-HER2 IgG1 to form a tandem IgG/IgA molecule (169). Similar to the IgGA, this molecule mediated enhanced neutrophil ADCC in comparison to both IgG and IgA2. However, by contrast, it was also capable of inducing NK-mediated ADCC due to retained Fc γ RIIIA binding (169), albeit lower than compared to afucosylated IgG1. Also in contrast to IgGA, tandem IgG/IgA also bound FcRn with a similar affinity to hIgG1 and had a correspondingly similar half-life to IgG1 *in vivo*, therefore overcoming one of the main limitations of IgA. This can be expected as the CH2–CH3 interface contains the IgG binding site for FcRn (170), and is maintained in this molecule. Finally, considering that this study focused on HER2 as a target, comparing anti-CD20 mAbs with a tandem IgG/IgA backbone with cross-isotype IgGA *in vivo* would be worthwhile to identify the most effective molecule.

In summary, IgA mAbs clearly engage various effector mechanisms and can exploit additional killing pathways (i.e., *via* CD89) compared to IgG. Although IgA in itself may not be able to replace IgG due to reasons of half-life and manufacturability, various chimeric fusions or combination regimens have been designed or suggested that combine the beneficial aspects of both IgG and IgA. It would be interesting to assess how these novel agents influence resistance mechanisms following anti-CD20 mAb therapy. For example, is trogocytosis (120) still induced by chimeric IgG/A molecules and how does this compare to wild-type IgA and G? As highlighted previously (109), an advantage of utilizing IgA mAbs is that interaction with the inhibitory Fc γ RIIB, known to limit effector cell activity (102), would not be expected. Similarly, IgA mAbs would not be expected to interact with Fc γ RIIB on the surface of malignant B-cells, thus limiting Fc γ RIIB-mediated modulation and removal of CD20/antibody complexes from the cell surface (73, 121). It would be interesting to assess how modulation compares with IgG/A chimeras, and whether further modifying these chimeras can reduce Fc γ RIIB binding to improve efficacy/limit resistance mechanisms.

IgE As an Alternative Immunoglobulin Class for mAb Therapies

Further to IgA, the anti-tumor potential of IgE has recently been identified, leading to suggestions that IgE may be an alternative

Ig class for mAb therapeutics. Although IgE is widely recognized as an Ig class implicated in allergy and responses to parasites, Nigro et al. have recently shown that IgE has a role in immune surveillance following tumor challenge (171). Various models were utilized to show that control of tumor growth was mediated in an IgE- and Fc epsilon receptor (FcεRI)-dependent manner, with an additional role for CD8⁺ T cells. Further to showing that tumors induce effective IgE responses that can limit tumor growth in a tumor challenge setting, this highlights that the FcεRI–IgE axis is worth considering in the setting of mAb therapy.

In the setting of anti-CD20, Teo et al. showed that an IgE mAb was capable of activating and inducing cytotoxicity, in an antigen-specific manner, through cells typically involved in allergic responses, namely mast cells or eosinophils derived from cord blood (172). The authors also highlighted the limitation of studies involving PBMCs as effectors (173), where the poor responses observed with IgE mAb are not considered in the absence or paucity of IgE effector cells. Moreover, a crucial concern was highlighted, in that there is a risk of anaphylaxis in the setting of a large circulating tumor burden following anti-CD20 IgE therapy (172). This prevented *in vivo* assessment of IgE anti-CD20 in this setting. It, therefore, needs to be considered how anti-CD20 IgE mAb therapies can be optimized to limit toxicity in patients. Nevertheless, an anti-MUC-1 mAb in a solid tumor model (4T1) was assessed (172). Although the efficacy of the mAb alone was limited, when utilizing a slightly different strategy to aid IgE and chemoattractant synthesis at the tumor site, tumor regression was observed. This highlights the importance of effector cell chemotaxis to the tumor site in the efficacy of anti-IgE mAb therapy.

Alternative IgG Isotypes

In addition to belonging to the IgG class, all but two (Panitumumab, hIgG2 anti-EGFR; ibritumomab, mouse IgG1 anti-CD20) of the direct-targeting mAbs approved for cancer treatment also have a hIgG1 Fc region (Table 1). Therefore, further to altering the class of Ig, changing the isotype has been considered as an alternative to anti-CD20 hIgG1 therapy.

IgG3 As an Alternative Isotype for mAb Therapies

Similar to IgG1, IgG3 is capable of effective Fc-dependent effector functions, such as CDC and ADCC (173). Indeed, IgG3 binds favorably to C1q (173) and broadly binds to FcγRs similar to IgG1 (174). There are numerous differences between IgG1 and 3, however. The latter bears an extremely long hinge region (IgG3—62 amino acids; IgG1—15) and is subject to extensive polymorphism (IgG3—13 allotypes; IgG1—4) (175). IgG3 also has a shorter half-life in comparison to other isotypes (176), an inability to bind protein A (173), and suffers from aggregation issues (177). In many ways, these mirror the disadvantages of IgA (see above). Despite this, some studies have suggested that IgG3 may be a more effective isotype for anti-CD20 mAbs, and have provided strategies to overcome the aforementioned limitations.

Rosner et al. showed that an IgG3 variant of rituximab (C2B8-IgG3) induces greater CDC than the corresponding IgG1 variant, with indications of superior sensitivity to low CD20 densities, such as in the case of CLL cells (177). However, ADCC and ADCP mediated by anti-CD20 IgG1 versus IgG3 were not compared in this study. This greater CDC capability of anti-CD20 IgG3 in comparison to IgG1 was also observed by Natsume et al., although they reported the converse for ADCC, with IgG1 being more effective (178). Similarly, although not in the context of anti-CD20, IgG1 was more capable of inducing ADCP of melanoma cells than IgG3 in a recent study (163) further suggesting that FcγR effector functions may not be improved in the setting of IgG3. A molecule comprising the advantageous regions of both IgG1 and IgG3 may, therefore, be beneficial. To this end, similar to the “cross-isotype” IgGA mAb described above, a domain switch variant of rituximab was generated by replacing the CH2/CH3 (Fc) of hIgG1 with same regions of IgG3. One particular mAb (1133) was identified that mediated superior CDC in comparison to hIgG1 and 3 and maintained a similar level of ADCC to hIgG1. Despite a potential benefit of the long hinge of IgG3 in introducing flexibility into the molecule (179), this finding suggests that the long hinge region of IgG3 is not responsible for the enhanced CDC (as 1133 contains the CH1 and hinge region of IgG1). Indeed, it has previously been suggested that a disulfide bond connecting the heavy chains, and not a hinge region *per se*, is required for CDC (179).

However, due to a loss in protein A binding, a known feature of IgG3 mAbs (173), and, therefore, concern about purification of the molecule on an industrial scale, the CH3 domain of mAb 1133 was further modified with increasing amounts of IgG1 sequence. This resulted in a molecule (113F) that was capable of binding to protein A and, importantly, maintained its superior CDC-inducing capabilities. Intriguingly, protein A and FcRn both bind to the CH2–CH3 interface of IgG (170), and the shorter half-life of IgG3 in comparison to hIgG1 has been shown to be caused by a single amino acid in this region (R435 in IgG3, H435 in other isotypes) that reduces the ability of IgG3 to compete with other isotypes of IgG for FcRn binding at pH 6 and, consequently, increases degradation (180). This is important to consider in the design of mAb therapeutics, but as 113F (in addition to binding to protein A) also contains the H435 site (178), poor pharmacokinetics should not be a limiting factor in this case. The polymorphic nature of IgG3 should nevertheless be considered if designing an IgG3 mAb therapy, as the IgG3 G3m(s,t) allotype contains H435 and has a correspondingly longer half-life (180).

Finally, it was shown that afucosylation improved the ADCC capacity of 113F but did not affect CDC, and that 113F resulted in more effective and prolonged B-cell depletion in a cynomolgus monkey model in comparison to IgG1 (178). This suggests that 113F may also be more effective than anti-CD20 hIgG1 in human patients.

In summary, studies with anti-CD20 mAbs have suggested that IgG3 mAbs may mediate more CDC in comparison to IgG1. However, this finding is inconsistent with distinct target antigens, indicating context-dependent rules. FcγR effector mechanisms of IgG3 may also be limited in comparison to

IgG1 *in vivo*, despite having a half-life enhancing mutation (see above), as highlighted in a recent study (163), although whether this translates to CD20 mAbs is unknown. Nevertheless, chimeric IgG1/3 molecules have been developed to combine the effector mechanisms of both IgG1 and 3.

OVERCOMING RESISTANCE AND THE IMMUNOSUPPRESSIVE MICROENVIRONMENT

The two decades of study of CD20 and its mAbs have provided us with a wealth of knowledge for how these reagents work and might be augmented. However, it has become increasingly clear that in addition to tumor intrinsic factors, such as expression level (181, 182), internalization (73), and trogocytosis (183), that tumor extrinsic factors associated with the tumor infiltrate are critical for determining mAb efficacy. A well-recognized hallmark of tumors is their ability to subvert and suppress the host immune system to facilitate their growth (184). Hematologic malignancies exhibit this trend and this may contribute to the tumor resistance often seen with anti-CD20 therapies. For example, CLL cells have been reported to produce the anti-inflammatory cytokine IL-10, which is able to reduce macrophage cytokine production (185), and also to impact upon the gene expression of both CD4⁺ and CD8⁺ T cells and viability of CD4⁺ T cells through surface expression of Fas ligand (186, 187). In addition, certain B-cell subsets have also been reported to produce IL-10, which may contribute to an anti-inflammatory environment within lymphoid organs (188). Tumor-associated macrophages frequently display a pro-tumor phenotype characterized by reduced phagocytosis and production of angiogenic factors (189).

Anti-CD20 therapy has been shown to be highly effective at rapidly depleting CD20 expressing cells from the circulation (190–192). However, circulating B-cells constitute only approximately 2% of the total B-cell population, and thus the penetration and efficacy of anti-CD20 mAbs into lymphoid tissues is crucial to their effectiveness (193). Mouse and primate studies have indicated that increasingly large doses are needed to deplete B-cells from bone marrow, spleen, and lymph nodes (191, 194, 195). As many malignant B-cells reside in lymphoid organs, if they are not eradicated by anti-CD20 therapy, they can act as disease reservoirs enabling re-emergence of the tumor leading to relapse and progression (196). Although next-generation mAb such as obinutuzumab that have followed rituximab have improved depletion efficacy, it is clear that further improvements in treatment regimens are still required (16).

OVERCOMING RESISTANCE TO ANTI-CD20 THERAPY THROUGH COMBINATION

As described above, an immunosuppressive microenvironment is one mechanism known to reduce the efficacy of mAb treatment. As such, attempts to alter the tumor microenvironment to a more favorable, inflammatory state have been made. Agonists

for toll-like receptors (TLRs), known to be important transducers of inflammatory signals in response to pathogen-associated molecular patterns such as LPS, are one group of molecules that have been tested. The synthetic oligodeoxynucleotide TLR agonist CpG, which activates TLR9, in combination with low dose radiotherapy has been reported to have a beneficial impact on B-cell lymphoma patients, inducing a T cell memory response in certain patients (197). Another TLR-9 agonist, 1018 ISS, has been combined with rituximab in follicular lymphoma and reported clinical response and tumor infiltration of CD8⁺ T cells and macrophages (198).

Another class of immunomodulatory molecules recently developed is STING agonists. These cyclic dinucleotides are sensed by cytosolic STING receptors (199). Normally involved in detection of DNA viruses, these agents can induce expression of IFN genes contributing to increased inflammation (199). *In vitro* and *in vivo* experiments using STING agonists have reported a phenotypic change of macrophages to a more inflammatory phenotype, increasing expression of activatory FcγRs crucial for antibody-mediated therapy (119). Accordingly, *in vivo* combination of STING ligands with anti-CD20 mAbs in a model of B-cell lymphoma overcame tumor-mediated immune suppression and resulted in curative treatments for 90% of mice (119).

An alternative immunomodulatory compound being assessed in combination with anti-CD20 mAb is lenalidomide. Lenalidomide is thought to act both through inducing tumor cell death and altering the tumor microenvironment and is approved for use in multiple myeloma (200). Lenalidomide combined with anti-CD20 mAb resulted in a significantly greater overall and complete response rates versus lenalidomide alone in a meta-analysis of refractory/relapsed CLL patients (201). Interestingly, lenalidomide plus anti-CD20 mAb achieved similar complete response rates to those seen with ibrutinib plus rituximab (see below) (202). Lenalidomide plus rituximab has also reported high response rates in untreated indolent NHL (203). The mechanistic basis for these effects is not yet fully resolved.

An alternative means of achieving immune conversion is by combining anti-CD20 mAbs with the so-called immunomodulatory antibodies. These antibodies differ from direct-targeting mAb in that they bind to cells of the immune system (rather than the tumor target) with the aim of activating or de-repressing them to elicit T cell responses. These mAb have achieved remarkable success in the last few years in treating certain patients with melanoma and lung cancer (6). The possibility of combining these agents with direct-targeting anti-CD20 mAbs has been proposed and tested in clinical trials. One such study combined the anti-programmed cell death-1 (PD-1) antibody pidilizumab with rituximab in the treatment of relapsed/refractory follicular lymphoma (204). Albeit for a small sample group, this study reported an increased complete response rate of 52% as compared to only 11% in patients receiving rituximab monotherapy. Nivolumab, another anti-PD-1 antibody, has already been approved for use in refractory Hodgkin's lymphoma after stem-cell transplant (205).

Following a phase I trial finding, ipilimumab was well tolerated in NHL and increased T cell proliferation. A combination trial

involving rituximab and the anti-CTLA-4 antibody ipilimumab is ongoing (206).

Other strategies for improving anti-CD20 therapy aim to address the results of tumor-mediated immune suppression, rather than reverse them *per se*. In our own work, we have attempted to counter the above described Fc γ RIIB-mediated internalization and inhibitory signaling which decreases CD20 therapy efficacy. This has been achieved through the use of an antagonistic anti-Fc γ RIIB antibody that prevents the *cis* binding of anti-CD20 antibody to Fc γ RIIB on the same cell, preventing internalization (131). Furthermore, this effect was also shown for combination of obinutuzumab and alemtuzumab with anti-Fc γ RIIB, suggesting a more general mechanism for reducing antibody internalization and increasing therapeutic efficacy. This has led to the initiation of a clinical trial for combining rituximab with anti-Fc γ RIIB in Fc γ RIIB⁺ cell malignancies (NCT02933320).

In addition to these immune-related interventions detailed above, recent years have also seen a rapid increase in drugs targeted at specific molecules thought to be involved in malignancy. In many cases, these have been combined with anti-CD20 mAbs for the treatment of B-cell malignancies. One such drug, ibrutinib (Ibruvica), an irreversible inhibitor of Btk has been approved for the treatment of relapsed/refractory CLL and several NHLs owing to high response rates and increased survival (207). Ibrutinib has been combined with anti-CD20 chemoimmunotherapy and yielded increased response rates in relapsed/refractory CLL over chemoimmunotherapy alone (202, 208). Ibrutinib has also been combined with anti-CD20 mAb in, among others, DLBCL and MCL and has achieved high response rates (209, 210). Further trials are ongoing combining ibrutinib with chemoimmunotherapy in various disease settings (211). Despite the apparent efficacy of this combination, ibrutinib has been reported to decrease antibody-induced cell-mediated effector mechanisms both *in vitro* and in cells from patients taking ibrutinib (212). This highlights the importance of considering drug combination mechanisms of action and appropriate dosing schedules to get the maximum benefit for patients.

Another small molecule inhibitor, idelalisib (Zydelig), approved for relapsed/refractory CLL and FL therapy is targeted at the delta isoform of the lipid kinase phosphoinositide-3-kinase (PI3K δ) (213, 214). This isoform is preferentially expressed in leukocytes and expressed in malignant B-cells (215, 216). Targeting of PI3K δ has shown to be effective in the treatment of B-cell malignancies, although toxicity issues have prevented idelalisib from becoming a front line therapy (217, 218). Combination of idelalisib and rituximab was found to be superior to idelalisib alone in relapsed/refractory CLL, and addition of idelalisib to bendamustine–rituximab therapy for CLL patients with a poor prognosis has shown to improve progression-free survival (219, 220). Idelalisib has also shown efficacy in several NHLs as monotherapy and in combination with rituximab and bendamustine (221, 222). Recent work from our group has revealed the pro-apoptotic BH3-only protein Bim to be key to the *in vivo* therapeutic mechanism of PI3K δ inhibition. Addition of a PI3K δ inhibitor to anti-CD20 mAb therapy reduced the accumulation of leukemia cells in the E μ -Tcl1 transgenic mouse model, and also improved survival compared to anti-CD20 mAb or PI3K δ inhibitor alone, in a Bim-dependent

manner (223). Furthermore, combination of a PI3K δ inhibitor with a BCL-2 inhibitor was more effective than either agent alone, reducing leukemic burden by 95% (223).

Venetoclax (Venclexta) is another small molecule inhibitor that targets BCL-2 and is approved for the treatment of relapsed/refractory CLL with 17p chromosomal deletions, based on high response rates in heavily pretreated patients (224, 225). This molecule has also been trialed in combination with rituximab in relapsed/refractory CLL, with high response levels reported (86% overall response rate) (226). Trials combining venetoclax with obinutuzumab are also underway, with preliminary data suggesting that it is highly efficacious in relapsed/refractory and untreated CLL in elderly patients (227, 228). Importantly, venetoclax has been reported to be efficacious in CLL patients who have failed previous kinase inhibitor therapy, such as ibrutinib or idelalisib (229). Another anti-BCL-2 drug, the antisense oligonucleotide Oblimersen sodium, has been tested in combination with rituximab and found to be beneficial in patients with relapsed/refractory NHL (230).

Although segregated in this review by mechanism, combinations of multiple drugs with differing mechanisms of action are being examined alongside anti-CD20 therapy. For example, TG Therapeutics are currently recruiting patients with relapsed/refractory CLL to a trial combining ublituximab (a glycoengineered anti-CD20 antibody) with TGR-1202 (a PI3K δ inhibitor) and pembrolizumab (anti-PD-1 antibody). Whether such an approach is efficacious or indeed viable in terms of health economics remains to be seen.

BISPECIFIC ANTIBODIES (bsAbs)

A further therapeutic approach that is currently being trialed in the clinic is the use of bsAbs. Multiple technologies have been developed for producing bsAbs, incorporating additional Fab domains in various positions and with altered Fc backbone engineering to ensure appropriate heavy chain pairing (231). A bsAb targeting CD19 and CD3 has already achieved approval for relapsed/refractory acute lymphoblastic leukemia (232). An anti-CD20/CD22 bsAb has shown enhanced preclinical activity over the combination of the two parental antibodies, inducing greater apoptosis *in vitro* and improved overall survival and tumor shrinkage *in vivo* (233). Combination of two anti-CD20 mAbs (a type I and a type II) into a tetravalent bsAb produced a molecule that induced enhanced direct cell death over the combination of parental Abs and retained equivalent CDC (234). Furthermore, this molecule had a more potent anti-tumor activity than the combined parental antibodies *in vivo*.

Attempts to increase engagement of the target cell with effector cells using bsAbs have also been made. One example is a CD20(2) \times Fc γ RIIIA tribody that binds target CD20 and effector Fc γ RIIIA, irrespective of the V/F158 polymorphism. This construct was superior to rituximab in terms of cell line and patient lymphoma cell lysis, NK-mediated tumor cell killing, and also B-cell depletion in whole blood, and functioned to deplete human B-cells in a mouse model reconstituted with a humanized hematopoietic system (235). A CD20/CD3 bsAb tested in multiple *in vivo* models appeared to act primarily through CD3 expressing

cells, rather than the antibody Fc region of this bispecific humanized IgG (236). Some of these bsAbs, such as the CD20/CD3 molecules REGN1979 (237) and FBTA05 (238), have entered clinical trials for B-cell lymphoma. Despite the termination of the clinical trial for FBTA05, this antibody has been used on compassionate grounds in children with B-cell malignancies refractory to conventional therapy, with some positive results (239).

CD20 MAB IN AUTOIMMUNE SETTINGS

In addition to the treatment of B-cell malignancies, many of the same therapeutic principles learnt from the study of anti-CD20 mAb can be applied to other disease settings, namely autoimmune disease. The rationale for B-cell depletion in autoimmune diseases such as rheumatoid arthritis (RA) is based on the (albeit incompletely understood) role of these cells in disease pathogenesis, namely differentiation into autoantibody-secreting plasma cells and antigen presentation to T cells, and the consequent expectation that their depletion will restore self-tolerance, as discussed in depth elsewhere (240). Nevertheless, it was shown in a double-blind randomized control trial that treating RA patients with rituximab resulted in both prolonged B-cell depletion and significant improvements in symptoms in comparison to methotrexate-treated patients (241). Moreover, a combination of rituximab and methotrexate increased the percentage of patients with improvements in symptoms at 48 weeks post-treatment (241). As a consequence of this (and other studies), rituximab is now FDA-approved for the treatment of RA, as well as the anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV), Wegener's Granulomatosis and Microscopic Polyangiitis (<https://www.fda.gov/Drugs/DrugSafety/ucm109106.htm>). However, contrary to indications of efficacy (242), rituximab showed no significant clinical benefit over control arms in randomized clinical trials of both extrarenal (243) and renal (lupus nephritis) (244) systemic lupus erythematosus (SLE) patients. Nevertheless, it has been estimated that rituximab is used off-label in approximately 0.5–1.5% of SLE patients in Europe, seemingly as a last resort in patients with worse disease (245).

As may be expected, a requirement for FcγRs in the mechanism of action of rituximab in autoimmune disease (as for B-cell malignancies) has been indicated in studies such as by Quartuccio et al., whereby clinical responses of RA patients were significantly greater at 6 months post-rituximab in FcγRIIIA V/V patients (246). It is noteworthy that the depletion of B-cells by rituximab may be variable (between patients) and incomplete in autoimmune disease. In the setting of RA, for example, a sensitive flow cytometry technique was used to detect remaining B-cells, and patients with complete depletion of B-cells after a single rituximab infusion had favorable clinical responses in comparison to patients with partial depletion (247). Similarly, when the same methodology was applied to SLE, all patients with complete B-cell depletion had a clinical response to rituximab, which contrasts to patients with incomplete B-cell depletion (248). Intriguingly, a significantly lower depletion of B-cells from SLE patients was observed in comparison to B-cells from RA patients or healthy donors when treated with anti-CD20 mAb in whole blood assays (249).

Several mechanisms may help to explain the variable and/or incomplete B-cell depletion observed with rituximab in autoimmune disease. This may be linked to levels of B-cell-activating factor (BAFF), which is known to increase in RA patients treated with rituximab in periods of B-cell depletion (240). Indeed, a recent retrospective study analyzed two cohorts of AAV patients and showed that a single nucleotide polymorphism in BAFF (TNFSF13B) was associated with responses to rituximab treatment (250). Although the authors of this study conceded that further mechanistic studies are required, this indicates that responses to B-cell depletion may be predicted in advance of rituximab treatment in the future (similar to FcγR polymorphisms and degree of B-cell depletion mentioned above), and patients given alternative therapies instead. Modulation of FcγRIIB/rituximab complexes may, as for malignant B-cells (73, 121), also be a relevant resistance mechanism in the setting of autoimmune B-cells, as indicated in *in vitro* studies (249) (see below). Finally, results from animal models of SLE have suggested that inefficient depletion in this disease may be due to the presence of autoantibody ICs (251). Recent studies employing chronic viral infection models, also characterized by excessive ICs, have lent support to the hypothesis that high concentrations of ICs may inhibit antibody effector mechanisms (252, 253). Both of these studies utilized anti-CD20 mAb and showed that chronically infected mice were incapable of depleting CD20⁺ cells (252, 253). This suggests that high levels of circulating ICs should be a concern in setting of anti-CD20 therapy and may result in inefficient B-cell depletion in patients.

Nevertheless, considering such indications of incomplete B-cell depletion using rituximab in autoimmune disease, one fundamental question is how the depletion of B-cells can be improved in the setting of autoimmune disease. Employing next-generation mAbs is an option. To this end, although a non-glyco-engineered type II anti-CD20 mAb induced greater depletion of B-cells in comparison to rituximab in a whole blood assay (249), suggesting a role for the type II nature of the mAb rather than a change in glycosylation, depletion was further increased with the glycomodified (afucosylated) type II mAb obinutuzumab (17). The greater depletion mediated by type II anti-CD20 corresponded to less internalization from the surface of B-cells from healthy donors and RA/SLE patients (249). In the setting of SLE, B-cell depletion by rituximab correlated with the level of surface accessible CD20, and the difference between B-cell cytotoxicity mediated by type I versus type II anti-CD20 mAb correlated with degree of internalization (249). Internalization mediated by type I anti-CD20 could be partially inhibited by use of blocking anti-FcγRIIB mAb (249). It can, therefore, be hypothesized that a combination of rituximab with an anti-FcγRIIB mAb will increase the efficiency of autoimmune B-cell depletion, for reasons including blockade of such FcγRIIB-mediated modulation, or FcγRIIB-mediated inhibition of activatory signaling on effector cells (102). Further still, alternative anti-CD20 mAbs have also been/are being developed for the treatment of other autoimmune diseases, namely the humanized mAb veltuzumab for the treatment of ITP (in addition to CLL/NHL) (20), which has a single amino acid change in the complementary determining region (CDR) 3 V_H in comparison to rituximab, and framework regions/Fc domains from the anti-CD22 mAb epratuzumab (21);

and ocrelizumab for the treatment of multiple sclerosis (MS) (Table 1). Notably, ocrelizumab was recently shown to significantly decrease disease progression in a phase III trial of primary progressive MS when compared with placebo (19) and was successful in two other trials (18), leading to its FDA approval. Alternatively, the glycoengineered anti-CD20 mAb ublituximab (Table 1) is also in clinical trials for the treatment of MS (25) for reasons of increased ADCC/potency (see above). Nevertheless, as with RA (241), the clinical benefit observed following B-cell depletion with anti-CD20 in MS further emphasizes a role of these cells in autoimmune disease pathogenesis (19).

A final factor to consider is the existence of serological evidence of autoimmunity that can precede the development of overt disease by years, as reviewed elsewhere (254, 255). It has, therefore, been questioned whether the development of autoimmune disease can be prevented/delayed. Studies such as PRAIRI (256) have, therefore, tested this, by infusing autoantibody-positive patients that do not yet have overt RA with a single infusion of rituximab (1,000 mg) and prospectively monitoring for disease onset versus placebo controls. The early results indicate that this strategy is able to delay disease onset (256).

CONCLUSION AND SUMMARY

Anti-CD20 mAbs have now been with us as approved clinical reagents for 20 years. As highlighted in Figure 1, their

development and study has fostered a large amount of our current knowledge of therapeutic mAb mechanisms of action and what makes an effective therapeutic target and mAb. In the next 5 years, an increasing number of combination strategies will be investigated in order to improve on the current levels of success. Coupled to this will be an increasing number of new mAb formats, aiming to take advantage of the knowledge gained to date. One important aspect of this development will be an in depth understanding of the disease microenvironment in each case. For example, to improve responses in CLL may not require the same developments as required for NHL and similarly the specific pathologies relating to RA, SLE, and MS may not involve similar solutions.

More widely, we can expect the learnings gleaned from the study of CD20 antibodies will flow into developments for other mAb specificities; particularly where target cell deletion is required. So, in answer to the question “What have we learnt from targeting CD20 and where are we going?” the response should be “a huge amount” and “to an era of combination and advanced antibody engineering leading to improved responses for patients.”

AUTHOR CONTRIBUTIONS

MM and RS wrote the manuscript and both contributed equally. MC edited and wrote the manuscript.

REFERENCES

- Feugier P. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas. *Future Oncol* (2015) 11(9):1327–42. doi:10.2217/fon.15.57
- Gurcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. *Int Immunopharmacol* (2009) 9(1):10–25. doi:10.1016/j.intimp.2008.10.004
- Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med* (2002) 346(4):235–42. doi:10.1056/NEJMoa011795
- Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. *Blood* (2010) 116(12):2040–5. doi:10.1182/blood-2010-03-276246
- Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. *Drugs* (2010) 70(11):1445–76. doi:10.2165/11201110-000000000-00000
- Lee CS, Cragg M, Glennie M, Johnson P. Novel antibodies targeting immune regulatory checkpoints for cancer therapy. *Br J Clin Pharmacol* (2013) 76(2):233–47. doi:10.1111/bcp.12164
- Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. *J Exp Med* (2013) 210(9):1695–710. doi:10.1084/jem.20130579
- Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. OX40 engagement depletes intratumoral Tregs via activating FcγR3s, leading to antitumor efficacy. *Immunol Cell Biol* (2014) 92(6):475–80. doi:10.1038/icb.2014.26
- Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, et al. Activating FcγR3 contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. *J Exp Med* (2013) 210(9):1685–93. doi:10.1084/jem.20130573
- Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. *J Clin Oncol* (2002) 20(10):2453–63. doi:10.1200/JCO.2002.11.076
- Marcus R. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma. *Semin Oncol* (2005) 32(1 Suppl 1):S36–43. doi:10.1053/j.seminoncol.2005.01.012
- Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. *J Immunol* (2006) 177(1):362–71. doi:10.4049/jimmunol.177.1.362
- Teeling JL, French RR, Cragg MS, van den Brakel J, Ployter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. *Blood* (2004) 104(6):1793–800. doi:10.1182/blood-2004-01-0039
- Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. *Blood* (2010) 115(22):4393–402. doi:10.1182/blood-2009-06-225979
- Golay J, Da Roit F, Bologna L, Ferrara C, Leusen J, Rambaldi A, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. *Blood* (2013) 122(20):3482–91. doi:10.1182/blood-2013-05-504043
- Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *N Engl J Med* (2014) 370(12):1101–10. doi:10.1056/NEJMoa1313984
- Reddy V, Klein C, Isenberg DA, Glennie MJ, Cambridge G, Cragg MS, et al. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. *Rheumatology (Oxford)* (2017) 56(7):1227–37. doi:10.1093/rheumatology/kex067

18. Reichert JM. Antibodies to watch in 2017. *MAbs* (2017) 9(2):167–81. doi:10.1080/19420862.2016.1269580
19. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. *N Engl J Med* (2016) 376(3):209–20. doi:10.1056/NEJMoa1606468
20. Milani C, Castillo J. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. *Curr Opin Mol Ther* (2009) 11(2):200–7.
21. Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. *Blood* (2009) 113(5):1062–70. doi:10.1182/blood-2008-07-168146
22. Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, et al. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma. *Clin Cancer Res* (2012) 18(5):1395–403. doi:10.1158/1078-0432.ccr-11-0850
23. Cheney CM, Stephens DM, Mo X, Rafiq S, Butchar J, Flynn JM, et al. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. *MAbs* (2014) 6(3):749–55. doi:10.4161/mabs.28282
24. Sharman JP, Farber CM, Mahadevan D, Schreeder MT, Brooks HD, Kolibaba KS, et al. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. *Br J Haematol* (2017) 176(3):412–20. doi:10.1111/bjh.14447
25. Lovett-Racke A, Liu Y, Racke M, Shubin R, Wray S, Su W, et al. Preliminary results of phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS) demonstrates rapid and robust B cell depletion (P6.348). *Neurology* (2017) 88(16 Suppl P6.348).
26. Wong SF. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. *Clin Ther* (2005) 27(6):684–94. doi:10.1016/j.clinthera.2005.06.003
27. Chu E. Panitumumab: a new anti-EGFR antibody for the treatment of advanced colorectal cancer. *Clin Colorectal Cancer* (2006) 6(1):13. doi:10.3816/CCC.2006.n.016
28. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. *J Clin Oncol* (2007) 25(13):1658–64. doi:10.1200/JCO.2006.08.1620
29. Dienstmann R, Tabernero J. Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer. *Curr Opin Investig Drugs* (2010) 11(12):1434–41.
30. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* (2001) 344(11):783–92. doi:10.1056/NEJM200103153441101
31. Maximiano S, Magalhaes P, Guerreiro MP, Morgado M. Trastuzumab in the treatment of breast cancer. *BioDrugs* (2016) 30(2):75–86. doi:10.1007/s40259-016-0162-9
32. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *N Engl J Med* (2012) 366(2):109–19. doi:10.1056/NEJMoa1113216
33. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. *J Clin Oncol* (2005) 23(11):2534–43. doi:10.1200/JCO.2005.03.184
34. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med* (2012) 367(19):1783–91. doi:10.1056/NEJMoa1209124
35. Krop IE, Kim SB, Gonzalez-Martín A, LoRusso PM, Ferrero JM, Smitt M, et al. Trastuzumab emtansine versus treatment of physician's choice for pre-treated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. *Lancet Oncol* (2014) 15(7):689–99. doi:10.1016/S1470-2045(14)70178-0
36. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. *N Engl J Med* (2010) 363(19):1812–21. doi:10.1056/NEJMoa1002965
37. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. *Nat Biotechnol* (2012) 30(7):631–7. doi:10.1038/nbt.2289
38. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. *J Immunol* (2011) 186(3):1840–8. doi:10.4049/jimmunol.1003032
39. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. *Lancet* (2016) 387(10027):1551–60. doi:10.1016/S0140-6736(15)01120-4
40. Dhillon S. Dinutuximab: first global approval. *Drugs* (2015) 75(8):923–7. doi:10.1007/s40265-015-0399-5
41. Hoy SM. Dinutuximab: a review in high-risk neuroblastoma. *Target Oncol* (2016) 11(2):247–53. doi:10.1007/s11523-016-0420-2
42. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. *Blood* (2002) 99(10):3554–61. doi:10.1182/blood.V99.10.3554
43. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. *J Clin Oncol* (2007) 25(35):5616–23. doi:10.1200/JCO.2007.12.9098
44. Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. *Lancet* (2016) 388(10043):488–97. doi:10.1016/S0140-6736(16)30587-6
45. Shirley M. Olaratumab: first global approval. *Drugs* (2017) 77(1):107–12. doi:10.1007/s40265-016-0680-2
46. Reichert JM. Approved antibodies. *Antibody Soc* [updated 2017 May 22]. Available from: www.antibodysociety.org
47. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. *J Immunol* (1980) 125(4):1678–85.
48. Ishibashi K, Suzuki M, Sasaki S, Imai M. Identification of a new multigene four-transmembrane family (MS4A) related to CD20, HTm4 and beta sub-unit of the high-affinity IgE receptor. *Gene* (2001) 264(1):87–93. doi:10.1016/S0378-1119(00)00598-9
49. Oettgen HC, Bayard PJ, Van Ewijk W, Nadler LM, Terhorst CP. Further biochemical studies of the human B-cell differentiation antigens B1 and B2. *Hybridoma* (1983) 2(1):17–28. doi:10.1089/hyb.1983.2.17
50. Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. *Semin Hematol* (2010) 47(2):107–14. doi:10.1053/j.seminhematol.2010.01.001
51. Oldham RJ, Cleary KLS, Cragg MS. CD20 and its antibodies: past, present, and future. *For Immunopathol Dis Therap* (2014) 5(1–2):7–23. doi:10.1615/ForumImmunDisTher.2015014073
52. Polyak MJ, Li H, Shariat N, Deans JP. CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. *J Biol Chem* (2008) 283(27):18545–52. doi:10.1074/jbc.M800784200
53. Uchida J, Lee Y, Hasegawa M, Liang Y, Bradney A, Oliver JA, et al. Mouse CD20 expression and function. *Int Immunol* (2004) 16(1):119–29. doi:10.1093/intimm/dxh009
54. Walshe CA, Beers SA, French RR, Chan CH, Johnson PW, Packham GK, et al. Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling. *J Biol Chem* (2008) 283(25):16971–84. doi:10.1074/jbc.M708459200
55. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. *J Clin Invest* (2010) 120(1):214–22. doi:10.1172/JCI40231
56. Morsy DE, Sanyal R, Zaiss AK, Deo R, Muruve DA, Deans JP. Reduced T-dependent humoral immunity in CD20-deficient mice. *J Immunol* (2013) 191(6):3112–8. doi:10.4049/jimmunol.1202098

57. Nadler LM, Ritz J, Hardy R, Pesando JM, Schlossman SF, Stashenko P. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. *J Clin Invest* (1981) 67(1):134–40. doi:10.1172/JCI110005
58. Kehrl JH, Riva A, Wilson GL, Thevenin C. Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. *Immunol Today* (1994) 15(9):432–6. doi:10.1016/0167-5699(94)90273-9
59. Mei HE, Schmidt S, Dörner T. Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. *Arthritis Res Ther* (2012) 14(Suppl 5):S1. doi:10.1186/ar3909
60. Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. *Arthritis Res Ther* (2013) 15(Suppl 1):S3. doi:10.1186/ar3908
61. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. *Curr Dir Autoimmun* (2005) 8:140–74. doi:10.1159/000082102
62. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. *J Clin Pathol* (1998) 51(5):364–9. doi:10.1136/jcp.51.5.364
63. Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. *Blood* (2003) 101(3):1045–52. doi:10.1182/blood-2002-06-1761
64. Xia MQ, Hale G, Waldmann H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. *Mol Immunol* (1993) 30(12):1089–96. doi:10.1016/0161-5890(93)90155-5
65. Cleary KLS, Chan HTC, James S, Glennie MJ, Cragg MS. Antibody distance from the cell membrane regulates antibody effector mechanisms. *J Immunol* (2017) 198(10):3999–4011. doi:10.4049/jimmunol.1601473
66. Deans JP, Robbins SM, Polyak MJ, Savage JA. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. *J Biol Chem* (1998) 273(1):344–8. doi:10.1074/jbc.273.1.344
67. Gupta N, DeFranco AL. Lipid rafts and B cell signaling. *Semin Cell Dev Biol* (2007) 18(5):616–26. doi:10.1016/j.semcdb.2007.07.009
68. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. *Blood* (2004) 103(7):2738–43. doi:10.1182/blood-2003-06-2031
69. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies: historical and future perspectives. *Haematologica* (2010) 95(1):135–43. doi:10.3324/haematol.2008.001628
70. Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. *Blood* (2011) 118(2):358–67. doi:10.1182/blood-2010-09-305847
71. Chan HT, Hughes D, French RR, Tutt AL, Walshe CA, Teeling JL, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. *Cancer Res* (2003) 63(17):5480–9.
72. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. *Blood* (2011) 117(17):4519–29. doi:10.1182/blood-2010-07-296913
73. Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. *Blood* (2010) 115(25):5191–201. doi:10.1182/blood-2010-01-263533
74. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. *Immunol Today* (1994) 15(9):450–4. doi:10.1016/0167-5699(94)90276-3
75. Cragg MS. CD20 antibodies: doing the time warp. *Blood* (2011) 118(2):219–20. doi:10.1182/blood-2011-04-346700
76. Weiner GJ. Rituximab: mechanism of action. *Semin Hematol* (2010) 47(2):115–23. doi:10.1053/j.seminhematol.2010.01.011
77. Cheadle EJ, Sidon L, Dovedi SJ, Melis MH, Alduaij W, Illidge TM, et al. The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab. *Br J Haematol* (2013) 162(6):842–5. doi:10.1111/bjh.12427
78. Degn SE, Thiel S. Humoral pattern recognition and the complement system. *Scand J Immunol* (2013) 78(2):181–93. doi:10.1111/sji.12070
79. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I – molecular mechanisms of activation and regulation. *Front Immunol* (2015) 6:262. doi:10.3389/fimmu.2015.00262
80. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. *J Clin Oncol* (2010) 28(21):3525–30. doi:10.1200/JCO.2010.27.9836
81. Diebold CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, et al. Complement is activated by IgG hexamers assembled at the cell surface. *Science* (2014) 343(6176):1260–3. doi:10.1126/science.1248943
82. de Jong RN, Beurskens FJ, Verploegen S, Strumane K, van Kampen MD, Voorhorst M, et al. A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. *PLoS Biol* (2016) 14(1):e1002344. doi:10.1371/journal.pbio.1002344
83. Cragg MS, Bayne MB, Tutt AL, French RR, Beers S, Glennie MJ, et al. A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. *Blood* (2004) 104(8):2540–2. doi:10.1182/blood-2004-05-1733
84. Nimmerjahn F, Gordon S, Lux A. FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. *Trends Immunol* (2015) 36(6):325–36. doi:10.1016/j.it.2015.04.005
85. Gul N, van Egmond M. Antibody-dependent phagocytosis of tumor cells by macrophages: a potent effector mechanism of monoclonal antibody therapy of cancer. *Cancer Res* (2015) 75(23):5008–13. doi:10.1158/0008-5472.CAN-15-1330
86. Hargreaves CE, Rose-Zerilli MJ, Machado LR, Iriyama C, Hollox EJ, Cragg MS. FcγR receptors: genetic variation, function, and disease. *Immunol Rev* (2015) 268(1):6–24. doi:10.1111/imr.12341
87. Wang SY, Weiner G. Complement and cellular cytotoxicity in antibody therapy of cancer. *Expert Opin Biol Ther* (2008) 8(6):759–68. doi:10.1517/14712598.8.6.759
88. Flannagan RS, Jaumouille V, Grinstein S. The cell biology of phagocytosis. *Annu Rev Pathol* (2012) 7:61–98. doi:10.1146/annurev-pathol-011811-132445
89. Braster R, O'Toole T, van Egmond M. Myeloid cells as effector cells for monoclonal antibody therapy of cancer. *Methods* (2014) 65(1):28–37. doi:10.1016/j.jymeth.2013.06.020
90. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. *Blood* (2002) 99(3):754–8. doi:10.1182/blood.V99.3.754
91. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. *J Clin Oncol* (2008) 26(11):1789–96. doi:10.1200/jco.2007.14.8957
92. Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, et al. Analysis of FcγR IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. *Clin Cancer Res* (2012) 18(12):3478–86. doi:10.1158/1078-0432.CCR-11-2294
93. Ghesquieres H, Cartron G, Seymour JF, Delfau-Larue MH, Offner F, Soubeyran P, et al. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. *Blood* (2012) 120(13):2650–7. doi:10.1182/blood-2012-05-431825
94. Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. *J Immunol* (2004) 172(5):3280–8. doi:10.4049/jimmunol.172.5.3280
95. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. *Blood* (2000) 95(12):3900–8.
96. Weng WK, Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. *Blood* (2001) 98(5):1352–7. doi:10.1182/blood.V98.5.1352
97. Wang SY, Racila E, Taylor RP, Weiner GJ. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated

- target cells is inhibited by the C3b component of complement. *Blood* (2008) 111(3):1456–63. doi:10.1182/blood-2007-02-074716
98. Wang SY, Veeramani S, Racila E, Cagley J, Fritzingier DC, Vogel CW, et al. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. *Blood* (2009) 114(26):5322–30. doi:10.1182/blood-2009-01-200469
 99. Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. *Clin Cancer Res* (2008) 14(20):6697–703. doi:10.1158/1078-0432.CCR-08-0745
 100. Jin X, Ding H, Ding N, Fu Z, Song Y, Zhu J. Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP. *J Hematol Oncol* (2012) 5:51. doi:10.1186/1756-8722-5-51
 101. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR gamma chain deletion results in pleiotropic effector cell defects. *Cell* (1994) 76(3):519–29. doi:10.1016/0092-8674(94)90115-5
 102. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. *Nat Med* (2000) 6(4):443–6. doi:10.1038/74704
 103. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. *J Exp Med* (2004) 199(12):1659–69. doi:10.1084/jem.20040119
 104. Minard-Colin V, Xiu Y, Poe JC, Horikawa M, Magro CM, Hamaguchi Y, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. *Blood* (2008) 112(4):1205–13. doi:10.1182/blood-2008-01-135160
 105. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, et al. Complement activation determines the therapeutic activity of rituximab in vivo. *J Immunol* (2003) 171(3):1581–7. doi:10.4049/jimmunol.171.3.1581
 106. Montalvo F, Garcia Z, Celli S, Breart B, Deguine J, Van Rooijen N, et al. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. *J Clin Invest* (2013) 123(12):5098–103. doi:10.1172/JCI70972
 107. Lee CH, Romain G, Yan W, Watanabe M, Charab W, Todorova B, et al. IgG Fc domains that bind C1q but not effector Fcgamma receptors delineate the importance of complement-mediated effector functions. *Nat Immunol* (2017) 18(8):889–98. doi:10.1038/ni.3770
 108. Tutt AL, James S, Laversin SA, Tipton TR, Ashton-Key M, French RR, et al. Development and characterization of monoclonal antibodies specific for mouse and human Fcgamma receptors. *J Immunol* (2015) 195:5503–16. doi:10.4049/jimmunol.1402988
 109. Dechant M, Vidarsson G, Stockmeyer B, Repp R, Glennie MJ, Gramatzki M, et al. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. *Blood* (2002) 100(13):4574–80. doi:10.1182/blood-2002-03-0687
 110. Nakagawa T, Natsume A, Satoh M, Niwa R. Nonfucosylated anti-CD20 antibody potentially induces apoptosis in lymphoma cells through enhanced interaction with FcγRIIIb on neutrophils. *Leuk Res* (2010) 34(5):666–71. doi:10.1016/j.leukres.2009.10.029
 111. Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, et al. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. *Cancer Cell* (2011) 19(1):101–13. doi:10.1016/j.ccr.2010.11.012
 112. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PH, Derer S, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. *J Immunol* (2010) 184(1):512–20. doi:10.4049/jimmunol.0900847
 113. Xu Y, Szalai AJ, Zhou T, Zinn KR, Chaudhuri TR, Li X, et al. Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. *J Immunol* (2003) 171(2):562–8. doi:10.4049/jimmunol.171.2.562
 114. White AL, Chan HT, Roghanian A, French RR, Mockridge CI, Tutt AL, et al. Interaction with FcgammaRIIb is critical for the agonistic activity of anti-CD40 monoclonal antibody. *J Immunol* (2011) 187(4):1754–63. doi:10.4049/jimmunol.1101135
 115. Li F, Ravetch JV. Antitumor activities of agonistic anti-TNFR antibodies require differential FcgammaRIIb coengagement in vivo. *Proc Natl Acad Sci U S A* (2013) 110(48):19501–6. doi:10.1073/pnas.1319502110
 116. de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. *Cancer Res* (2010) 70(8):3209–17. doi:10.1158/0008-5472.can-09-4109
 117. Lehmann CH, Baranska A, Heidkamp GF, Heger L, Neubert K, Luhr JJ, et al. DC subset-specific induction of T cell responses upon antigen uptake via Fcgamma receptors in vivo. *J Exp Med* (2017) 214(5):1509–28. doi:10.1084/jem.20160951
 118. Albanesi M, Mancardi DA, Jonsson F, Iannascoli B, Fiette L, Di Santo JP, et al. Neutrophils mediate antibody-induced antitumor effects in mice. *Blood* (2013) 122(18):3160–4. doi:10.1182/blood-2013-04-497446
 119. Dahal LN, Dou L, Hussain K, Liu R, Earley A, Cox KL, et al. STING activation reverses lymphoma-mediated resistance to antibody immunotherapy. *Cancer Res* (2017) 77(13):3619–31. doi:10.1158/0008-5472.can-16-2784
 120. Valgardsdottir R, Cattaneo I, Klein C, Introna M, Figliuzzi M, Golay J. Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B-cells opsonized with anti-CD20 antibodies. *Blood* (2017) 129(19):2636–44. doi:10.1182/blood-2016-08-735605
 121. Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HT, et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. *Blood* (2011) 118(9):2530–40. doi:10.1182/blood-2011-01-330357
 122. Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. *Cancer Res* (2011) 71(7):2411–6. doi:10.1158/0008-5472.can-10-2583
 123. Heineke MH, van Egmond M. Immunoglobulin A: magic bullet or Trojan horse? *Eur J Clin Invest* (2017) 47(2):184–92. doi:10.1111/eci.12716
 124. Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab. *Blood* (2009) 113(16):3809–12. doi:10.1182/blood-2008-10-185280
 125. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. *J Clin Invest* (2002) 110(1):71–9. doi:10.1172/jci15640
 126. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. *J Exp Med* (2002) 195(12):1653–9. doi:10.1084/jem.20020338
 127. Clynes R, Maizes JS, Guinamard R, Ono M, Takai T, Ravetch JV. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. *J Exp Med* (1999) 189(1):179–85. doi:10.1084/jem.189.1.179
 128. Abes R, Gelize E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. *Blood* (2010) 116(6):926–34. doi:10.1182/blood-2009-10-248609
 129. DiLillo DJ, Ravetch JV. Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. *Cell* (2015) 161:1035–45. doi:10.1016/j.cell.2015.04.016
 130. Ren Z, Guo J, Liao J, Luan Y, Liu Z, Sun Z, et al. CTLA-4 limits anti-CD20-mediated tumor regression. *Clin Cancer Res* (2017) 23(1):193–203. doi:10.1158/1078-0432.ccr-16-0040
 131. Roghanian A, Teige I, Martensson L, Cox KL, Kovacek M, Ljungars A, et al. Antagonistic human FcgammaRIIb (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. *Cancer Cell* (2015) 27(4):473–88. doi:10.1016/j.ccell.2015.03.005
 132. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. *Cancer Cell* (2010) 18(2):160–70. doi:10.1016/j.ccr.2010.06.014
 133. Ortiz DF, Lansing JC, Rutitzky L, Kurtagic E, Prod’homme T, Choudhury A, et al. Elucidating the interplay between IgG-Fc valency and FcgammaR activation for the design of immune complex inhibitors. *Sci Transl Med* (2016) 8(365):365ra158. doi:10.1126/scitranslmed.aaf9418
 134. Tao MH, Morrison SL. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. *J Immunol* (1989) 143(8):2595–601.

135. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. *J Biol Chem* (2001) 276(9):6591–604. doi:10.1074/jbc.M009483200
136. Koide N, Nose M, Muramatsu T. Recognition of IgG by Fc receptor and complement: effects of glycosidase digestion. *Biochem Biophys Res Commun* (1977) 75(4):838–44. doi:10.1016/0006-291X(77)91458-9
137. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. *J Mol Biol* (2003) 325(5):979–89. doi:10.1016/S0022-2836(02)01250-0
138. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc gamma RIII and antibody-dependent cellular toxicity. *J Biol Chem* (2002) 277(30):26733–40. doi:10.1074/jbc.M202069200
139. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. *J Biol Chem* (2003) 278(5):3466–73. doi:10.1074/jbc.M210665200
140. Ferrara C, Stuart F, Sondermann P, Brunker P, Umama P. The carbohydrate at Fc gamma RIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. *J Biol Chem* (2006) 281(8):5032–6. doi:10.1074/jbc.M510171200
141. Yu X, Marshall MJE, Cragg MS, Crispin M. Improving antibody-based cancer therapeutics through glycan engineering. *BioDrugs* (2017) 31:151–66. doi:10.1007/s40259-017-0223-8
142. de Romeuf C, Dutertre CA, Le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of Fc gamma RIIIa/CD16. *Br J Haematol* (2008) 140(6):635–43. doi:10.1111/j.1365-2141.2007.06974.x
143. Le Garff-Tavernier M, Decocq J, de Romeuf C, Parizot C, Dutertre CA, Chapiro E, et al. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. *Leukemia* (2011) 25(1):101–9. doi:10.1038/leu.2010.240
144. Bruggeman CW, Dekkers G, Bentlage AEH, Treffers LW, Nagelkerke SQ, Lissenberg-Thunnissen S, et al. Enhanced effector functions due to antibody defucosylation depend on the effector cell Fc gamma receptor profile. *J Immunol* (2017) 199(1):204–11. doi:10.4049/jimmunol.1700116
145. Sazinsky SL, Ott RG, Silver NW, Tidor B, Ravetch JV, Wittrup KD. Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. *Proc Natl Acad Sci USA* (2008) 105(51):20167–72. doi:10.1073/pnas.0809257105
146. Jung ST, Kelton W, Kang TH, Ng DT, Andersen JT, Sandlie I, et al. Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high Fc gamma RIIa affinity and selectivity. *ACS Chem Biol* (2013) 8(2):368–75. doi:10.1021/cb300455f
147. Caaveiro JM, Kiyoshi M, Tsumoto K. Structural analysis of Fc/Fc gamma R complexes: a blueprint for antibody design. *Immunol Rev* (2015) 268(1):201–21. doi:10.1111/imr.12365
148. Mimoto F, Kuramochi T, Katada H, Igawa T, Hattori K. Fc engineering to improve the function of therapeutic antibodies. *Curr Pharm Biotechnol* (2016) 17(15):1298–314. doi:10.2174/1389201017666160824161854
149. Mimoto F, Katada H, Kadono S, Igawa T, Kuramochi T, Muraoka M, et al. Engineered antibody Fc variant with selectively enhanced Fc gamma RIIb binding over both Fc gamma RIIa(R131) and Fc gamma RIIa(H131). *Protein Eng Des Sel* (2013) 26(10):589–98. doi:10.1093/protein/gzt022
150. Lu Y, Vernes JM, Chiang N, Ou Q, Ding J, Adams C, et al. Identification of IgG(1) variants with increased affinity to Fc gamma RIIIa and unaltered affinity to Fc gamma RI and FcRn: comparison of soluble receptor-based and cell-based binding assays. *J Immunol Methods* (2011) 365(1–2):132–41. doi:10.1016/j.jim.2010.12.014
151. Nimmerjahn F, Ravetch J. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. *Science* (2005) 310(5753):1510–2. doi:10.1126/science.1118948
152. Stavenhagen JB, Gorlatov S, Tuaille N, Rankin CT, Li H, Burke S, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fc gamma receptors. *Cancer Res* (2007) 67(18):8882–90. doi:10.1158/0008-5472.CAN-07-0696
153. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to Fc gamma RIIa enhances macrophage phagocytosis of tumor cells. *Mol Cancer Ther* (2008) 7(8):2517–27. doi:10.1158/1535-7163.MCT-08-0201
154. Zhang D, Goldberg MV, Chiu ML. Fc engineering approaches to enhance the agonism and effector functions of an anti-OX40 antibody. *J Biol Chem* (2016) 291(53):27134–46. doi:10.1074/jbc.M116.757773
155. Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. *J Immunol* (2002) 169(9):5171–80. doi:10.4049/jimmunol.169.9.5171
156. Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. *MAbs* (2011) 3(5):422–30. doi:10.4161/mabs.3.5.16983
157. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, et al. Enhanced antibody half-life improves in vivo activity. *Nat Biotechnol* (2010) 28(2):157–9. doi:10.1038/nbt.1601
158. Robbie GJ, Criste R, Dall'Acqua WF, Jensen K, Patel NK, Losonsky GA, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. *Antimicrob Agents Chemother* (2013) 57(12):6147–53. doi:10.1128/AAC.01285-13
159. Presta LG. Molecular engineering and design of therapeutic antibodies. *Curr Opin Immunol* (2008) 20(4):460–70. doi:10.1016/j.coi.2008.06.012
160. Monnet C, Jorieux S, Souyris N, Zaki O, Jacquet A, Fournier N, et al. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody. *MAbs* (2014) 6(2):422–36. doi:10.4161/mabs.27854
161. Morell A, Skvaril F, Nosedá G, Barandun S. Metabolic properties of human IgA subclasses. *Clin Exp Immunol* (1973) 13(4):521–8.
162. Stockmeyer B, Dechant M, van Egmond M, Tutt AL, Sundarapandian K, Graziano RF, et al. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. *J Immunol* (2000) 165(10):5954–61. doi:10.4049/jimmunol.165.10.5954
163. Braster R, Grewal S, Visser R, Einarsdottir HK, van Egmond M, Vidarsson G, et al. Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice. *PLoS One* (2017) 12(5):e0177736. doi:10.1371/journal.pone.0177736
164. Lohse S, Loew S, Kretschmer A, Jansen JHM, Meyer S, Ten Broeke T, et al. Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. *Br J Haematol* (2017). doi:10.1111/bjh.14624
165. Pascal V, Laffleur B, Debin A, Cuvillier A, van Egmond M, Drocourt D, et al. Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells. *Haematologica* (2012) 97(11):1686–94. doi:10.3324/haematol.2011.061408
166. Engelberts PJ, Voorhorst M, Schuurman J, van Meerten T, Bakker JM, Vink T, et al. Type I CD20 antibodies recruit the B cell receptor for complement-dependent lysis of malignant B cells. *J Immunol* (2016) 197:4829–37. doi:10.4049/jimmunol.1600811
167. Kelton W, Mehta N, Charab W, Lee J, Lee CH, Kojima T, et al. IgGA: a “cross-isotype” engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions. *Chem Biol* (2014) 21:1603–9. doi:10.1016/j.chembiol.2014.10.017
168. Li B, Xu L, Tao F, Xie K, Wu Z, Li Y, et al. Simultaneous exposure to Fc gamma R and Fc alpha R on monocytes and macrophages enhances antitumor activity in vivo. *Oncotarget* (2017) 8(24):39356–66. doi:10.18632/oncotarget.17000
169. Borrok MJ, Luheshi NM, Beyaz N, Davies GC, Legg JW, Wu H, et al. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with Fc alpha RI (CD89) binding. *MAbs* (2015) 7(4):743–51. doi:10.1080/19420862.2015.1047570
170. Wines BD, Powell MS, Parren PW, Barnes N, Hogarth PM. The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that

- recognized by neonatal FcR and protein A. *J Immunol* (2000) 164(10):5313–8. doi:10.4049/jimmunol.164.10.5313
171. Nigro EA, Brini AT, Yenagi VA, Ferreira LM, Achatz-Straussberger G, Ambrosi A, et al. Cutting edge: IgE plays an active role in tumor immunosurveillance in mice. *J Immunol* (2016) 197(7):2583–8. doi:10.4049/jimmunol.1601026
 172. Teo PZ, Utz PJ, Mollick JA. Using the allergic immune system to target cancer: activity of IgE antibodies specific for human CD20 and MUC1. *Cancer Immunol Immunother* (2012) 61(12):2295–309. doi:10.1007/s00262-012-1299-0
 173. Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. *J Exp Med* (1987) 166(5):1351–61. doi:10.1084/jem.166.5.1351
 174. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fc γ receptors and their polymorphic variants for human IgG subclasses. *Blood* (2009) 113(16):3716–25. doi:10.1182/blood-2008-09-179754
 175. Salfeld JG. Isotype selection in antibody engineering. *Nat Biotechnol* (2007) 25(12):1369–72. doi:10.1038/nbt1207-1369
 176. Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. *J Clin Invest* (1970) 49(4):673–80. doi:10.1172/jci106279
 177. Rosner T, Derer S, Kellner C, Dechant M, Lohse S, Vidarsson G, et al. An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels. *Br J Haematol* (2013) 161(2):282–6. doi:10.1111/bjh.12209
 178. Natsume A, In M, Takamura H, Nakagawa T, Shimizu Y, Kitajima K, et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. *Cancer Res* (2008) 68(10):3863–72. doi:10.1158/0008-5472.can-07-6297
 179. Brekke OH, Michaelsen TE, Sandlie I. The structural requirements for complement activation by IgG: does it hinge on the hinge? *Immunol Today* (1995) 16(2):85–90. doi:10.1016/0167-5699(95)80094-8
 180. Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. *Nat Commun* (2011) 2:599. doi:10.1038/ncomms1608
 181. Fang C, Zhuang Y, Wang L, Fan L, Wu YJ, Zhang R, et al. High levels of CD20 expression predict good prognosis in chronic lymphocytic leukemia. *Cancer Sci* (2013) 104(8):996–1001. doi:10.1111/cas.12192
 182. Tomita A. Genetic and epigenetic modulation of CD20 expression in B-cell malignancies: molecular mechanisms and significance to rituximab resistance. *J Clin Exp Hematop* (2016) 56(2):89–99. doi:10.3960/jslrt.56.89
 183. Taylor RP, Lindorfer MA. Fc γ -receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments. *Blood* (2015) 125(5):762–6. doi:10.1182/blood-2014-10-569244
 184. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* (2011) 144(5):646–74. doi:10.1016/j.cell.2011.02.013
 185. DiLillo DJ, Weinberg JB, Yoshizaki A, Horikawa M, Bryant JM, Iwata Y, et al. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. *Leukemia* (2013) 27(1):170–82. doi:10.1038/leu.2012.165
 186. Gorgun G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. *J Clin Invest* (2005) 115(7):1797–805. doi:10.1172/JCI24176
 187. Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, et al. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. *Blood* (1998) 91(11):4273–81.
 188. Iwata Y, Matsushita T, Horikawa M, DiLillo DJ, Yanaba K, Venturi GM, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. *Blood* (2011) 117(2):530–41. doi:10.1182/blood-2010-07-294249
 189. Rhee I. Diverse macrophages polarization in tumor microenvironment. *Arch Pharm Res* (2016) 39(11):1588–96. doi:10.1007/s12272-016-0820-y
 190. Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. *J Clin Oncol* (1999) 17(3):791–5. doi:10.1200/JCO.1999.17.3.791
 191. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. *Blood* (1994) 83(2):435–45.
 192. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. *Blood* (1994) 84(8):2457–66.
 193. Blum KS, Pabst R. Lymphocyte numbers and subsets in the human blood. Do they mirror the situation in all organs? *Immunol Lett* (2007) 108(1):45–51. doi:10.1016/j.imlet.2006.10.009
 194. Schroder C, Azimzadeh AM, Wu G, Price JO, Atkinson JB, Pierson RN. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. *Transpl Immunol* (2003) 12(1):19–28. doi:10.1016/S0966-3274(03)00059-5
 195. Alwayn IP, Xu Y, Basker M, Wu C, Buhler L, Lambrigts D, et al. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody. *Xenotransplantation* (2001) 8(3):157–71. doi:10.1034/j.1399-3089.2001.008003157.x
 196. Lykken JM, Tedder TF. The tumor microenvironment regulates CD19 and CD20 immunotherapy for lymphoma. *Cancer J* (2015) 21(4):351–6. doi:10.1097/PPO.0000000000000137
 197. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. *J Clin Oncol* (2010) 28(28):4324–32. doi:10.1200/JCO.2010.28.9793
 198. Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. *Br J Haematol* (2009) 146(3):282–91. doi:10.1111/j.1365-2141.2009.07773.x
 199. Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, et al. STING is a direct innate immune sensor of cyclic di-GMP. *Nature* (2011) 478(7370):515–8. doi:10.1038/nature10429
 200. Zeldis JB, Knight R, Hussein M, Chopra R, Muller G. A review of the history, properties, and use of the immunomodulatory compound lenalidomide. *Ann N Y Acad Sci* (2011) 1222:76–82. doi:10.1111/j.1749-6632.2011.05974.x
 201. Liang L, Zhao M, Zhu YC, Hu X, Yang LP, Liu H. Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis. *Ann Hematol* (2016) 95(9):1473–82. doi:10.1007/s00277-016-2719-6
 202. Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. *Lancet Oncol* (2014) 15(10):1090–9. doi:10.1016/S1470-2045(14)70335-3
 203. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemester FB, McLaughlin P, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. *Lancet Oncol* (2014) 15(12):1311–8. doi:10.1016/S1470-2045(14)70455-3
 204. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. *Lancet Oncol* (2014) 15(1):69–77. doi:10.1016/S1470-2045(13)70551-5
 205. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *N Engl J Med* (2015) 372(4):311–9. doi:10.1056/NEJMoa1411087
 206. Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. *Clin Cancer Res* (2009) 15(20):6446–53. doi:10.1158/1078-0432.CCR-09-1339
 207. Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. *Blood* (2015) 125(16):2497–506. doi:10.1182/blood-2014-10-606038
 208. Chanan-Khan A, Cramer P, Demirhan F, Fraser G, Silva RS, Grosicki S, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS):

- a randomised, double-blind, phase 3 study. *Lancet Oncol* (2016) 17(2):200–11. doi:10.1016/S1470-2045(15)00465-9
209. Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemester F, Westin J, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. *Lancet Oncol* (2016) 17(1):48–56. doi:10.1016/S1470-2045(15)00438-6
 210. Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorig S, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naïve patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. *Lancet Oncol* (2014) 15(9):1019–26. doi:10.1016/S1470-2045(14)70311-0
 211. Rosenthal A. Small molecule inhibitors in chronic lymphocytic lymphoma and B cell non-Hodgkin lymphoma. *Curr Hematol Malig Rep* (2017) 12(3):207–16. doi:10.1007/s11899-017-0383-0
 212. Da Roit F, Engelberts PJ, Taylor RP, Breij EC, Gritti G, Rambaldi A, et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. *Haematologica* (2015) 100(1):77–86. doi:10.3324/haematol.2014.107011
 213. Lannutti BJ, Meadows SA, Herman SEM, Kashishian A, Steiner B, Johnson AJ, et al. CAL-101, a p110 delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. *Blood* (2011) 117(2):591–4. doi:10.1182/blood-2010-03-275305
 214. Do B, Mace M, Rexwinkle A. Idelalisib for treatment of B-cell malignancies. *Am J Health Syst Pharm* (2016) 73(8):547–55. doi:10.2146/ajhp150281
 215. Chantry D, Vojtek A, Kashishian A, Holtzman DA, Wood C, Gray PW, et al. p110 delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. *J Biol Chem* (1997) 272(31):19236–41. doi:10.1074/jbc.272.31.19236
 216. Brown JR. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia. *Semin Oncol* (2016) 43(2):260–4. doi:10.1053/j.seminoncol.2016.02.004
 217. Barrientos JC. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. *Future Oncol* (2016) 12(18):2077–94. doi:10.2217/fo-2016-0003
 218. Lampon BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. *Blood* (2016) 128(2):195–203. doi:10.1182/blood-2016-03-707133
 219. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N Engl J Med* (2014) 370(11):997–1007. doi:10.1056/NEJMoa1315226
 220. Zelenetz AD, Robak T, Coiffier B, Delgado J, Marlton P, Adewoye AH, et al. Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia: results of a phase 3 randomized double-blind placebo-controlled study. *Blood* (2015) 126(23):LBA-5.
 221. de Vos S, Wagner-Johnston ND, Coutre SE, Flinn I, Schreeder MT, Fowler N, et al. Durable responses following treatment with the PI3K-delta inhibitor idelalisib in combination with rituximab, bendamustine, or both, in recurrent indolent non-Hodgkin lymphoma: phase I/II results. *Blood* (2014) 124(21):3063.
 222. Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. *Haematologica* (2017) 102(4):e156–9. doi:10.3324/haematol.2016.151738
 223. Carter MJ, Cox KL, Blakemore SJ, Turaj AH, Oldham RJ, Dahal LN, et al. PI3Kdelta inhibition elicits anti-leukemic effects through Bim-dependent apoptosis. *Leukemia* (2017) 31(6):1423–33. doi:10.1038/leu.2016.333
 224. Souers AJ, Levenson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. *Nat Med* (2013) 19(2):202–8. doi:10.1038/nm.3048
 225. Jones J, Mato AR, Coutre S, Wierda W, Choi MY, Davids MS, et al. Preliminary results of a phase 2, open-label study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with chronic lymphocytic leukemia relapsed after or refractory to ibrutinib or idelalisib therapy. *Blood* (2015) 126(23):715.
 226. Ma S, Brander DM, Seymour JF, Kipps TJ, Barrientos JC, Davids MS, et al. Deep and durable responses following venetoclax (ABT-199/GDC-0199) combined with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from a phase 1b study. *Blood* (2015) 126(23):830.
 227. Flinn IW, Brunvand M, Choi MY, Dyer MJS, Gribben J, Hillmen P, et al. Safety and efficacy of a combination of venetoclax (GDC-0199/ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia – results from a phase 1b study (GP28331). *Blood* (2015) 126(23):494.
 228. Fischer K, Fink AM, Bishop H, Dixon M, Bahlo J, Chol MY, et al. Results of the safety run-in phase of CLL14 (BO25323): a prospective, open-label, multicenter randomized phase III trial to compare the efficacy and safety of obinutuzumab and venetoclax (GDC-0199/ABT-199) with obinutuzumab and chlorambucil in patients with previously untreated CLL and coexisting medical conditions. *Blood* (2015) 126(23):496.
 229. Jones J, Choi MY, Mato AR, Furman RR, Davids MS, Heffner LT, et al. Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib. *Blood* (2016) 128(22):637.
 230. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemester F, et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. *Br J Haematol* (2008) 143(3):355–60. doi:10.1111/j.1365-2141.2008.07353.x
 231. Liu H, Saxena A, Sidhu SS, Wu D. Fc engineering for developing therapeutic bispecific antibodies and novel scaffolds. *Front Immunol* (2017) 8:38. doi:10.3389/fimmu.2017.00038
 232. Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. *Lancet Oncol* (2015) 16(1):57–66. doi:10.1016/S1470-2045(14)71170-2
 233. Tuscano JM, Ma Y, Martin SM, Kato J, O'Donnell RT. The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone. *Cancer Immunol Immunother* (2011) 60(6):771–80. doi:10.1007/s00262-011-0978-6
 234. Li B, Zhang X, Shi S, Zhao L, Zhang D, Qian W, et al. Construction and characterization of a bispecific anti-CD20 antibody with potent antitumor activity against B-cell lymphoma. *Cancer Res* (2010) 70(15):6293–302. doi:10.1158/0008-5472.CAN-10-0009
 235. Glorius P, Baerenwaldt A, Kellner C, Staudinger M, Dechant M, Stauch M, et al. The novel tribody [(CD20)(2)CD16] efficiently triggers effector cell-mediated lysis of malignant B cells. *Leukemia* (2013) 27(1):190–201. doi:10.1038/leu.2012.150
 236. Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, et al. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. *Sci Transl Med* (2015) 7(287):287ra70. doi:10.1126/scitranslmed.aaa4802
 237. Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. *Sci Rep* (2015) 5:17943. doi:10.1038/srep17943
 238. Buhmann R, Michael S, Juergen H, Horst L, Peschel C, Kolb HJ. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating phase I/II-trial. *J Transl Med* (2013) 11:160. doi:10.1186/1479-5876-11-160
 239. Schuster FR, Stanglmaier M, Woessmann W, Winkler B, Siepermann M, Meisel R, et al. Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies. *Br J Haematol* (2015) 169(1):90–102. doi:10.1111/bjh.13242
 240. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. *Nat Rev Immunol* (2006) 6(5):394–403. doi:10.1038/nri1838
 241. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. *N Engl J Med* (2004) 350(25):2572–81. doi:10.1056/NEJMoa032534

242. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. *Arthritis Rheum* (2002) 46(10):2673–7. doi:10.1002/art.10541
243. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. *Arthritis Rheum* (2010) 62(1):222–33. doi:10.1002/art.27233
244. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. *Arthritis Rheum* (2012) 64(4):1215–26. doi:10.1002/art.34359
245. Ryden-Aulin M, Boumpas D, Bultink I, Callejas Rubio JL, Caminal-Montero L, Castro A, et al. Off-label use of rituximab for systemic lupus erythematosus in Europe. *Lupus Sci Med* (2016) 3(1):e000163. doi:10.1136/lupus-2016-000163
246. Quartuccio L, Fabris M, Pontarini E, Salvin S, Zabotti A, Benucci M, et al. The 158VV Fcγ receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. *Ann Rheum Dis* (2014) 73(4):716–21. doi:10.1136/annrheumdis-2012-202435
247. Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. *Arthritis Rheum* (2008) 58(10):2993–9. doi:10.1002/art.23902
248. Vital EM, Dass S, Buch MH, Henshaw K, Pease CT, Martin MF, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. *Arthritis Rheum* (2011) 63(10):3038–47. doi:10.1002/art.30466
249. Reddy V, Cambridge G, Isenberg DA, Glennie MJ, Cragg MS, Leandro M. Internalization of rituximab and the efficiency of B cell depletion in rheumatoid arthritis and systemic lupus erythematosus. *Arthritis Rheumatol* (2015) 67(8):2046–55. doi:10.1002/art.39167
250. Alberici F, Smith RM, Fonseca M, Willcocks LC, Jones RB, Holle JU, et al. Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis. *J Allergy Clin Immunol* (2016) 139(5):1684–7. doi:10.1016/j.jaci.2016.08.051
251. Ahuja A, Teichmann LL, Wang H, Dunn R, Kehry MR, Shlomchik MJ. An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in lupus. *J Immunol* (2011) 187(7):3888–94. doi:10.4049/jimmunol.1101629
252. Yamada DH, Elsaesser H, Lux A, Timmerman JM, Morrison SL, de la Torre JC, et al. Suppression of Fcγ receptor-mediated antibody effector function during persistent viral infection. *Immunity* (2015) 42:379–90. doi:10.1016/j.immuni.2015.01.005
253. Wieland A, Shashidharamurthy R, Kamphorst AO, Han JH, Aubert RD, Choudhury BP, et al. Antibody effector functions mediated by Fcγ receptors are compromised during persistent viral infection. *Immunity* (2015) 42:367–78. doi:10.1016/j.immuni.2015.01.009
254. Malmstrom V, Catrina AI, Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. *Nat Rev Immunol* (2017) 17(1):60–75. doi:10.1038/nri.2016.124
255. Robertson JM, James JA. Preclinical systemic lupus erythematosus. *Rheum Dis Clin North Am* (2014) 40(4):621–35. doi:10.1016/j.rdc.2014.07.004
256. Gerlag D, Safy M, Maijer K, de Hair M, Tas S, Starmans-Kool M, et al. OP0182 prevention of rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease: the prairie study. *Ann Rheum Dis* (2016) 75 (Suppl 2):125–6. doi:10.1136/annrheumdis-2016-eular.6042

Conflict of Interest Statement: MC is a retained consultant for Bioinvent and has performed educational and advisory roles for Baxalta and GLG. He has received research funding from Roche, Gilead, and GSK. MM and RS both receive BBSRC iCASE studentships and are partly funded by Roche and Promega, respectively.

The reviewer MI and handling editor declared their shared affiliation.

Copyright © 2017 Marshall, Stopforth and Cragg. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.